

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese population: a cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574
Article Type:	Original research
Date Submitted by the Author:	31-Jan-2021
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhang, Yuwei; Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese population: a**  
5  
6 **cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Yuwei Zhang<sup>1</sup>,  
12  
13  
14 Chengfu Xu<sup>1,\*</sup>  
15

16  
17 <sup>1</sup> Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20  
21  
22  
23

24  
25 **\*Corresponding author:**  
26

27 Chengfu Xu, M.D.  
28

29  
30 Department of Gastroenterology,  
31

32 The First Affiliated Hospital, Zhejiang University School of Medicine  
33

34  
35 79 Qingchun Road, Hangzhou 310003, China  
36

37  
38 Tel: 0086-571-87236863  
39

40  
41 E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn)  
42

43 # Jinhua Wang and Yishu Chen contributed equally to this work.  
44  
45  
46  
47  
48  
49

50  
51 **Key words:** Hyperuricemia; non-obese; Risk factor; Cross-sectional study;  
52  
53 Nonalcoholic fatty liver disease;  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Objectives:** Hyperuricemia is closely related to metabolic diseases and has become a major public health problem. This study aims to investigate the prevalence and risk factors of hyperuricemia in non-obese Chinese population.

**Design:** Cross-sectional study

**Setting:** Large general hospital can provide health checkups in Hangzhou, China.

**Participants:** 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Excluded criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; and (3) those with a history of malignancy.

**Primary and secondary outcome measures:** The prevalence and risk factors of hyperuricemia in Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, with 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women elder than 50 years old. The prevalence of hyperuricemia increased significantly in metabolically unhealthy normal weight participants than that in metabolically healthy normal weight participants. Hyperuricemic participants had higher prevalence of metabolic syndrome and fatty liver disease than hyperuricemia-free participants. Age, waist circumference, creatinine, blood urea nitrogen, excessive drinking and fatty liver were associated with risk of hyperuricemia in both genders.

1  
2  
3  
4 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
5  
6 Non-obese hyperuricemic participants also had many metabolic disorders. Clinicians  
7  
8 should pay attention to serum uric acid levels in non-obese individuals, especially in  
9  
10 metabolically unhealthy individuals.  
11  
12  
13  
14  
15  
16

### 17 **Strengths and limitations of this study**

18  
19 The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
20

21  
22 The prevalence of hyperuricemia increased significantly in metabolically unhealthy  
23  
24 normal weight participants compared with metabolically healthy normal weight  
25  
26 participants.  
27  
28

29  
30 Hyperuricemia in non-obese people was also accompanied by many metabolic  
31  
32 disorders.  
33

34  
35 It is a single-center cross-sectional study, and further multi-center cohort studies are  
36  
37 needed.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Uric acid is the end-product of purine metabolism in humans and it has the ability to scavenge oxygen radicals and protect the erythrocyte membrane from lipid oxidation<sup>1</sup>. Hyperuricemia is a common metabolic disease that closely related to gout<sup>2</sup>. Over the last decade, more and more studies have found that hyperuricemia is related to obesity, hypertension, dyslipidemia, chronic kidney disease, and nonalcoholic fatty liver disease (NAFLD)<sup>3-7</sup>. The prevalence of hyperuricemia varies across different populations and different areas. In the United States, approximately 21.4% adults met the criteria for hyperuricemia in the first decade of the 21<sup>th</sup> century<sup>8</sup>. A previous nationally representative survey showed that the prevalence of hyperuricemia was 6.4% among middle-aged and elderly Chinese<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>.

Many metabolic-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglycerides, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglycerides to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid levels, whereas serum HDL-C levels were significantly inversely associated<sup>11</sup>. Juraschek *et al.* found that individuals with uncontrolled blood pressure and additional cardiovascular disease risk factors had a 4-fold or greater prevalence of hyperuricemia<sup>12</sup>.

It is generally believed that obesity is closely related to metabolic related

1  
2  
3  
4 diseases, and increased the risk of diabetes, NAFLD and hyperuricemia. Recently,  
5  
6 more and more studies focus on the metabolic disorders in non-obese people. Some  
7  
8 studies have shown that non-obese people also have a high prevalence of NAFLD.  
9  
10 For example, we previously reported that the prevalence of NAFLD in the non-obese  
11  
12 Chinese population was 7.3%<sup>13</sup>. A study from Japan warned that more than 60% of  
13  
14 Japanese diabetic subjects are non-obese<sup>14</sup>. This means that it is important to assess  
15  
16 metabolic abnormalities in non-obese people. So far, there is still a paucity of studies  
17  
18 about the assessment of hyperuricemia in non-obese people.  
19  
20  
21  
22  
23  
24

25 In this study, we conducted a cross-sectional analysis in a non-obese Chinese  
26  
27 population to evaluate the prevalence of hyperuricemia and determine its associated  
28  
29 risk factors.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Methods

### Study population

We conducted a cross-sectional study among adults who took their health checkups at First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. We excluded the following participants: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; and (3) those with a history of malignancy. A total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study.

### Clinical evaluations

We collected the standing height, body weight, waist circumference and blood pressure for all participants. Height and weight were measured while participants were wearing light clothing without shoes. BMI (kg/m<sup>2</sup>) is calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical values. The values were measured by Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol intake included the frequency of alcohol consumption per week and the usual amount per day. Questions about smoking history included the daily smoking count and years of smoking.

### Diagnostic criteria and definitions

1  
2  
3  
4 BMI is the only criterion that defines obesity. Non-obese is defined as BMI < 24  
5  
6 kg/m<sup>2</sup>, and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as  
7  
8 alcohol consumption >210 g/week for men or >70 g/week for women. Hyperuricemia  
9  
10 was defined as serum uric acid levels >420 μmol/L for men or >360 μmol/L for  
11  
12 women, and/or taking medication for hyperuricemia.  
13  
14  
15

16  
17 Fatty liver was diagnosed by abdominal ultrasound examination. Trained  
18  
19 ultrasonographers performed abdominal ultrasound examinations with a Toshiba  
20  
21 Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
22  
23 blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis  
24  
25 of fatty liver were based on those suggested by the Chinese Liver Disease  
26  
27 Association<sup>15</sup>.  
28  
29  
30  
31

32  
33 Metabolic syndrome was defined by the modified National Cholesterol  
34  
35 Education Program Adult Treatment Panel III report. For a participant to be defined  
36  
37 as having metabolic syndrome they must have three or more of the following factors:  
38  
39 (1) central obesity, defined as waist circumference > 102 cm for men or > 88 cm  
40  
41 for women; (2) raised triglyceride level, defined as triglycerides ≥ 1.7 mmol/L or  
42  
43 specific treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as  
44  
45 HDL cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated  
46  
47 blood pressure, defined as systolic blood pressure ≥130 mmHg or diastolic blood  
48  
49 pressure ≥85 mmHg, or treatment of previously diagnosed hypertension; and (5)  
50  
51 raised fasting blood sugar, defined as fasting blood sugar ≥6.1 mmol/L, or previously  
52  
53 diagnosed type 2 diabetes. Metabolically unhealthy were defined as participants met  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 the criterion of metabolic syndrome.  
5  
6  
7  
8

### 9 **Statistical analysis**

10  
11 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
12  
13 Continuous variables were presented as medians and interquartile range. They were  
14 compared by Student's *t* test or Mann-Whitney *U* test, one-way ANOVA with post  
15 hoc Tukey's test, or Kruskal-Wallis test with Bonferroni correction as appropriate.  
16  
17 Categorical variables were compared using the  $\chi^2$  test. A stepwise logistic regression  
18 analysis was performed to examine the relationship between hyperuricemia and  
19 anthropometric or biochemical variables (probability to enter = 0.05 and probability  
20 to remove = 0.10). A *P* value <0.05 (two-tailed) was considered to be statistically  
21 significant.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Ethics**

39  
40 All participants were verbally informed about the study's aim and procedures, and  
41 voluntarily consented to participant. The subject information was anonymized at  
42 collection and prior to analysis. All methods were performed in accordance with the  
43 approved guidelines. The study was approved by Clinical Research Ethics Committee  
44 of the First Affiliated Hospital, Zhejiang University School of Medicine  
45  
46  
47  
48  
49  
50  
51  
52  
53 (No.2021015).  
54  
55  
56  
57  
58  
59  
60

## Results

### Prevalence of hyperuricemia in non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a median age of 49.0 were included in this study. The overall prevalence of hyperuricemia was 9.4%, and were 16.3% and 4.6% in males and females, respectively. In non-obese males, the prevalence of hyperuricemia was stable under the age of 50, and gradually decreased after 50 years of age. Conversely, in non-obese females, the prevalence of hyperuricemia was decreased under the age of 50, and gradually increased after 50 years of age. An interesting finding is that the prevalence of hyperuricemia in females even higher than that in males after the ages of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants had greater BMI and waist circumference, higher diastolic blood pressure, and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), blood urea nitrogen (BUN), and creatinine than hyperuricemia-free participants.

### Association of hyperuricemia with metabolic disorders in non-obese population

We classified all non-obese participants into metabolically healthy normal weight (MHNW) and metabolically unhealthy normal weight (MUHNW), according to their metabolic status. We found that MUHNW participants had significantly higher

1  
2  
3  
4 prevalence of hyperuricemia than MHNW participants. In detail, the prevalence of  
5  
6 hyperuricemia increased from 15.6% in MHNW participants to 26.7% in MUHNW  
7  
8 participants in males. Similarly, the prevalence of hyperuricemia increased from 4.1%  
9  
10 in MHNW participants to 16.3% in MUHNW participants in females (Figure 2).  
11  
12  
13

14 We were also analyzed the prevalence of metabolic disorders in non-obese with or  
15  
16 without hyperuricemia. We found that the prevalence of metabolic syndrome and fatty  
17  
18 liver disease were significantly higher in hyperuricemic participants than in  
19  
20 hyperuricemia-free participants. Male hyperuricemic participants had higher  
21  
22 prevalence of raised triglyceride level and reduced HDL-C than hyperuricemia-free  
23  
24 participants. Female hyperuricemic participants had higher prevalence of raised  
25  
26 triglyceride level, reduced HDL-C, elevated blood pressure, and raised fasting blood  
27  
28 sugar than hyperuricemia-free participants (Table 2). However, the prevalence of  
29  
30 diabetes was not different between the two groups (Table 2).  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 **Risks of hyperuricemia among non-obese population**

42  
43 We analyzed the risk factors of hyperuricemia by stepwise logistic regression  
44  
45 analysis. The multivariable model showed that age, waist circumference, creatinine,  
46  
47 BUN, excessive drinking and presence of fatty liver were associated with increased  
48  
49 risks of hyperuricemia in both genders. Elevated serum levels of AST, total  
50  
51 cholesterol, HDL-C and LDL-C were associated with increased risks of  
52  
53 hyperuricemia in males. Elevated diastolic blood pressure, ALT, and triglyceride were  
54  
55 associated with increased risks of hyperuricemia in females (Table 3).  
56  
57  
58  
59  
60

## Discussion

This study investigated the prevalence and risks of hyperuricemia in non-obese Chinese adults. We found that the prevalence of hyperuricemia was 9.4% in non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, creatinine, BUN, excessive drinking and presence of fatty liver were associated with risk of hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, which is lower than that in the previously reported general population in East Asia<sup>10, 16</sup>. We found that among non-obese individuals, the overall prevalence of hyperuricemia in men was higher than that in women. However, the prevalence of hyperuricemia increased greatly in women older than 50 years, and the prevalence even exceeded that in men after the age of 65 years. This phenomenon was also found in other studies<sup>17, 18</sup>. This is primarily attributable to sex hormone effects on renal urate transport. It has been reported that estrogen affected serum uric acid levels through renal clearance, secretion and reabsorption. Young adult women have lower serum urate levels than young adult men, but the onset of menopause is associated with increased serum urate levels<sup>19</sup>.

Some studies have reported the interaction between hyperuricemia and NAFLD. We previously reported that hyperuricemia is independently associated with risk of NAFLD<sup>7</sup>. Our previous prospective study also found that NAFLD was strongly associated with increased risk of incident hyperuricemia<sup>20</sup>. In this study, we found fatty liver is an independent risk factor for hyperuricemia in non-obese population.

1  
2  
3  
4 These evidences indicated that hyperuricemia and NAFLD could cause and worsen  
5  
6 each other. This interaction still existed in non-obese population and resulted in a  
7  
8 more deteriorated metabolic status.  
9

10  
11 MUHNW generally defined as normal-weight with metabolic syndrome and it has  
12  
13 raised considerable scientific interest<sup>21</sup>. Individuals with a metabolically unhealthy  
14  
15 profile were associated with several health issues and a higher healthcare and  
16  
17 loss-of-productivity costs<sup>22</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
18  
19 higher than that in MHNW individuals, and the risk was higher than the relative risk  
20  
21 in those with metabolically healthy obesity (MHO)<sup>23</sup>. It is not rare to find MUHNW  
22  
23 individuals who have a worse prognosis of diabetes than MHO individuals<sup>24</sup>. In this  
24  
25 study, we found that the prevalence of hyperuricemia increased significantly in  
26  
27 MUHNW participants compared with that in MHNW participants. This phenomenon  
28  
29 was more obvious in women. This reminds us that we should pay more attention to  
30  
31 the serum uric acid levels in MUHNW individuals.  
32  
33  
34  
35  
36  
37  
38  
39

40  
41 We next assessed the comorbidity of other metabolic disorders in non-obese  
42  
43 hyperuricemia patients. We found that the prevalence of metabolic syndrome and  
44  
45 fatty liver disease in non-obese hyperuricemic participants were higher than that in  
46  
47 hyperuricemia-free controls. This indicated that hyperuricemia in non-obese people is  
48  
49 also accompanied by many metabolic disorders. Non-obese hyperuricemic individuals  
50  
51 also need to intervene in uric acid levels actively to reduce the risk of comorbid  
52  
53 metabolic disorders.  
54  
55  
56  
57

58  
59 Several limitations are acknowledged in this study. First, it is a single-center  
60

1  
2  
3  
4 cross-sectional study. Our sample size may be insufficient to represent the entire  
5  
6 Chinese adult population, and further multi-center cohort studies are needed. Second,  
7  
8 dietary information was not collected, although dietary intake could be a cofactor  
9  
10 associated with hyperuricemia. Some studies have showed that fructose-enriched food  
11  
12 and drink could increase serum UA levels<sup>25</sup>. Meanwhile, this study diagnosed  
13  
14 non-obese participants by the BMI but did not include waist circumference and  
15  
16 waist-to-hip ratio. Some central obese patients would be mixed in non-obese  
17  
18 participants.  
19  
20  
21  
22  
23

24  
25 In conclusion, our cross-sectional study showed that the prevalence of  
26  
27 hyperuricemia was 9.4% in non-obese Chinese adults. The prevalence of  
28  
29 hyperuricemia increased significantly in MUHNW participants compared with  
30  
31 MHNW participants. Hyperuricemia in non-obese people was also accompanied by  
32  
33 many metabolic disorders. Therefore, clinicians need to pay attention to serum uric  
34  
35 acid levels in non-obese patients, especially in metabolically unhealthy individuals.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Fundings**

This work was supported by National Natural Science Foundation of China (Nos. 81722009, and 81770573), Key Research and Development Program of Zhejiang Province (No. 2020C03033), and the Fundamental Research Funds for the Central Universities (No. 2018XZZX002-10, and 2019QNA7034).

**Conflicts of interest**

The authors declare no conflicts of interest.

**Author Contributions:**

Conceived and designed the experiment: X.C.F. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.Y.W. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

**Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

**Data Availability Statement**

Data are available upon reasonable request

## References

1. Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. *Nat Commun* 2012; 3: 764.
2. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
3. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
4. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
5. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
6. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
7. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
8. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
9. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
12. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
13. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
14. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
15. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
16. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol* 2018; 37(9): 2529-38.
17. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
18. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
19. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
20. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
21. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol* 2020; 19(4): 359-66.
22. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
23. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4): 558-66.
24. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
25. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n =1967)	With hyperuricemia (n =382)		Without hyperuricemia (n =3226)	With hyperuricemia (n =156)	
Age (year)	47.0(18.0)	45.0(17.0)	0.004	43.0(16.0)	47.5(21.0)	0.004
WC (cm)	82.0(7.0)	84.0(7.0)	<0.001	74.0(8.0)	76.0(9.0)	<0.001
BMI (kg/m <sup>2</sup> )	22.29(2.21)	22.73(1.93)	<0.001	21.09(2.72)	21.96(2.67)	<0.001
SBP (mmHg)	121.0(22.0)	123.0(23.0)	0.086	112.0(21.0)	119.0(27.0)	<0.001
DBP (mmHg)	75.0(15.0)	77.0(15.3)	<0.001	68.0(14.0)	72.5(16.8)	<0.001
ALT (U/L)	18.0(11.0)	21.0(15.0)	<0.001	13.0(7.0)	15.0(10.8)	<0.001
AST (U/L)	19.0(6.0)	20.0(8.0)	<0.001	17.0(5.0)	19.0(8.5)	<0.001
GGT (U/L)	21.0(18.0)	30.0(28.0)	<0.001	13.0(7.0)	16.0(13.0)	<0.001
Creatinine (µmol/L)	80.0(14.0)	84.0(13.3.0)	<0.001	59.0(11.0)	63.0(12.0)	<0.001
BUN (mmol/L)	4.94(1.5)	5.22(1.65)	0.001	4.43(1.49)	4.88(1.78)	<0.001
TG (mmol/L)	1.17(0.74)	1.56(1.26)	<0.001	0.89(0.56)	1.17(0.94)	<0.001
TC (mmol/L)	4.45(1.11)	4.65(1.14)	<0.001	4.45(1.17)	4.69(1.27)	0.003
HDL-C (mmol/L)	1.17(0.38)	1.10(0.34)	<0.001	1.42(0.44)	1.31(0.52)	0.001
LDL-C (mmol/L)	2.58(0.91)	2.69(1.01)	0.02	2.45(0.91)	2.62(0.98)	0.032
VLDL-C (mmol/L)	0.6(0.34)	0.73(0.46)	<0.001	0.5(0.29)	0.62(0.40)	<0.001
FBS (mmol/L)	4.84(0.65)	4.9(0.63)	0.139	4.75(0.57)	4.92(0.73)	<0.001
Excessive drinking (%)	14.0%	19.4%	0.007	1.4%	3.8%	0.016
Smoking history (%)	39.0%	42.9%	0.15	1.4%	1.3%	0.906
SUA (µmol/L)	336.0(70.0)	452.5(57.0)	<0.001	256.0(61.0)	388.0(38.5)	<0.001

Data are expressed as the medians (IQR) because the data were not normally distributed.

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglycerides; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.

Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		<i>P</i> -value	Female		<i>P</i> -value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.971 (0.960-0.981)	<0.001	0.970 (0.952-0.988)	0.001
WC (cm)	1.056 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.019
DBP (mmHg)	/		1.032 (1.015-1.049)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.012 (1.002-1.022)	0.013	/	
Creatinine (µmol/L)	1.026 (1.016-1.037)	<0.001	1.046 (1.027-1.065)	<0.001
BUN (mmol/L)	1.112 (1.006-1.228)	0.037	1.290 (1.116-1.490)	0.001
TG (mmol/L)	/		1.403 (1.183-1.664)	<0.001
TC (mmol/L)	2.681 (1.902-3.777)	<0.001	/	
HDL-C (mmol/L)	0.381 (0.242-0.598)	<0.001	/	
LDL-C (mmol/L)	0.398 (0.265-0.597)	<0.001	/	
Excessive drinking	1.486 (1.089-2.029)	0.013	3.324 (1.328-8.319)	0.010
NAFLD	1.918 (1.445-2.547)	<0.001	1.861 (1.140-3.037)	0.013

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglycerides; TC: total cholesterol; WC: waist circumference

1  
2  
3  
4 **Figure Legend**  
5

6 Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants  
7

8  
9 Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or  
10

11 metabolically unhealthy participants. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R1
Article Type:	Original research
Date Submitted by the Author:	16-Jun-2021
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhang, Yuwei; Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Yuwei Zhang<sup>1</sup>,  
12  
13  
14 Chengfu Xu<sup>1,\*</sup>  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20  
21

22  
23  
24  
25 **\*Corresponding author:**  
26

27 Chengfu Xu, M.D.  
28

29  
30 Department of Gastroenterology,  
31

32 The First Affiliated Hospital, Zhejiang University School of Medicine  
33

34  
35 79 Qingchun Road, Hangzhou 310003, China  
36

37  
38 Tel: 0086-571-87236863  
39

40  
41 E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn)  
42  
43  
44

45  
46 # Jinghua Wang and Yishu Chen contributed equally to this work.  
47  
48  
49

50  
51 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
52

53  
54 Nonalcoholic fatty liver disease;  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Cross-sectional study

**Setting:** Large general hospital can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy, and (4) those under urate lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women older than 50 years old. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than that in metabolically healthy participants with normal weight. Hyperuricemic participants showed higher prevalence of metabolic syndrome and fatty liver disease than hyperuricemia-free participants. Age, waist circumference,

1  
2  
3  
4 eGFR, blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10

11 Non-obese hyperuricemic participants also showed multiple metabolic disorders.  
12

13  
14 Clinicians should pay attention to serum uric acid levels in non-obese population,  
15  
16 especially in metabolically unhealthy individuals.  
17  
18

### 19 20 21 22 **Strengths and limitations of this study** 23

24 This study included a large sample size of participants (more than 5000 adults), which  
25  
26 made our findings more convincing.  
27  
28

29  
30 This study first estimated the prevalence of hyperuricemia among non-obese adults in  
31  
32 China.  
33

34  
35 The multivariate logistic model was used to correct selection biases by adjusting for  
36  
37 potential confounders.  
38

39  
40 It is a single-center cross-sectional study, and further multi-center cohort studies are  
41  
42 needed.  
43  
44

45  
46 Patients currently undergoing uric acid treatment were excluded, which may cause a  
47  
48 certain bias in the prevalence of hyperuricemia in this study.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder that is commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is related to other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and areas. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than that of NHANES 1988–1994<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. The findings above all call for more attention on the health problem of hyperuricemia from a metabolic perspective.

Many metabolism-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglycerides, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglycerides to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid level, whereas serum HDL-C level was significantly inversely associated<sup>12</sup>. Juraschek *et al.* found

1  
2  
3  
4 that individuals with uncontrolled blood pressure and additional cardiovascular  
5  
6 disease risk factors had a 4-fold or greater prevalence of hyperuricemia<sup>13</sup>.  
7  
8

9 It is generally believed that obesity is closely related to metabolism-related  
10  
11 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
12  
13 Recently, more and more studies shifted their attention to metabolic disorders in  
14  
15 non-obese people. Some studies have shown that non-obese people also present a high  
16  
17 prevalence of NAFLD. For example, as we previously reported, the prevalence of  
18  
19 NAFLD in non-obese Chinese population was 7.3%<sup>14</sup>. A study from Japan warned  
20  
21 that more than 60% of Japanese diabetic subjects are non-obese<sup>15</sup>. The findings  
22  
23 suggest that it be important to assess metabolic abnormalities in non-obese people. So  
24  
25 far, there is still a paucity of studies on hyperuricemia in non-obese people.  
26  
27  
28  
29  
30  
31

32 In this study, we conducted a cross-sectional analysis in a non-obese Chinese  
33  
34 population to evaluate the prevalence of hyperuricemia and determine its associated  
35  
36 factors.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Study population

We conducted a cross-sectional study among adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. All participants received medical history collection, anthropometric testing, blood examination, and abdominal ultrasound examination. We excluded the following participants: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had a BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, a total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study (Figure S1).

### Clinical evaluations

We collected standing height, body weight, waist circumference and blood pressure from all participants. Height and weight were measured while participants were wearing light clothes without shoes. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical parameters. The values were measured by Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol intake

1  
2  
3  
4 included frequency of alcohol consumption (per week) and usual amount per day.  
5

6 Questions about smoking history included daily smoking count and years of smoking.  
7  
8  
9

### 10 11 **Diagnostic criteria and definitions** 12

13  
14 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
15 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
16 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia was  
17 defined as serum uric acid level >420 μmol/L for men or >360 μmol/L for women,  
18 and/or taking medication for hyperuricemia. The factor eGFR (estimated glomerular  
19 filtration rate) was calculated using the modified MDRD formula<sup>16</sup>.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 All individuals included in the study underwent abdominal ultrasound  
31 examination, which was performed by trained ultrasonographers with a Toshiba  
32 Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
33 blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis  
34 of fatty liver were based on those suggested by the Chinese Liver Disease  
35 Association<sup>17</sup>.  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 Metabolic syndrome was defined by the modified National Cholesterol  
46 Education Program Adult Treatment Panel III report<sup>18</sup>. Participants diagnosed with  
47 metabolic syndrome must have three or more of the following factors: (1) central  
48 obesity, defined as waist circumference > 102 cm for men or > 88 cm for women;  
49 (2) raised serum triglyceride level, defined as triglycerides ≥ 1.7 mmol/L or specific  
50 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated blood  
5  
6 pressure, defined as systolic blood pressure  $\geq$ 130 mmHg or diastolic blood pressure  
7  
8  $\geq$ 85 mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
9  
10 blood sugar, defined as fasting blood sugar  $\geq$ 6.1 mmol/L, or previously diagnosed  
11  
12 type 2 diabetes. Metabolically unhealthy was defined as participants met the criterion  
13  
14 of metabolic syndrome.  
15  
16  
17  
18  
19  
20  
21

### 22 **Statistical analysis**

23  
24 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
25  
26 Continuous variables were presented as mean and 95% confidence interval (CI) and  
27  
28 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
29  
30 variables were compared using the  $\chi^2$  test. A stepwise logistic regression analysis was  
31  
32 performed to examine the relationship between hyperuricemia and anthropometric or  
33  
34 biochemical variables (probability to enter = 0.05 and probability to remove = 0.10).  
35  
36  
37  
38 A *P* value <0.05 (two-tailed) was considered to be statistically significant.  
39  
40  
41  
42  
43  
44  
45

### 46 **Ethics**

47  
48 All participants were verbally informed about the study's aim and procedures, and  
49  
50 gave voluntary consent. The subject information was anonymized at collection and  
51  
52 prior to analysis. All methods were performed in accordance with the approved  
53  
54 guidelines. The study was approved by Clinical Research Ethics Committee of The  
55  
56 First Affiliated Hospital, Zhejiang University School of Medicine (No.2021015).  
57  
58  
59  
60

## Patient and Public Involvement

Patients or the public were not involved in the design, or conduct, or report, or dissemination plan of our research.

For peer review only

## Results

### Prevalence of hyperuricemia in non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4%, and 16.3% and 4.6% in males and females, respectively. In non-obese males, the prevalence of hyperuricemia was stable under the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased under the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants had greater BMI and waist circumference, higher diastolic blood pressure, and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT), blood urea nitrogen (BUN), creatinine and eGFR than hyperuricemia-free participants.

### Association of hyperuricemia with metabolic disorders in non-obese population

We classified all non-obese participants into metabolically healthy normal weight (MHNW) and metabolically unhealthy normal weight (MUHNW), according to their metabolic status. We found that MUHNW participants had significantly higher

1  
2  
3  
4 prevalence of hyperuricemia than MHNW participants. In detail, the prevalence of  
5  
6 hyperuricemia increased from 15.6% in MHNW participants to 26.7% in MUHNW  
7  
8 participants in males ( $p<0.001$ ). Similarly, the prevalence of hyperuricemia increased  
9  
10 from 4.1% in MHNW participants to 16.3% in MUHNW participants in females  
11  
12 ( $p<0.001$ ) (Figure 2).  
13  
14  
15

16  
17 We also analyzed the prevalence of metabolic disorders in non-obese individuals  
18  
19 with or without hyperuricemia. We found that the prevalence of metabolic syndrome  
20  
21 and that of fatty liver disease were significantly higher in hyperuricemic participants  
22  
23 than in hyperuricemia-free participants. Male hyperuricemic participants had higher  
24  
25 prevalence of raised triglyceride level and reduced HDL-C than hyperuricemia-free  
26  
27 participants. Female hyperuricemic participants had higher prevalence of raised  
28  
29 triglyceride level, reduced HDL-C, elevated blood pressure, and raised fasting blood  
30  
31 sugar than hyperuricemia-free participants (Table 2). However, the prevalence of  
32  
33 diabetes was not different between the two groups (Table 2).  
34  
35  
36  
37  
38  
39  
40  
41  
42

### 43 **Factors associated with hyperuricemia among non-obese population**

44  
45 We analyzed the factors associated with hyperuricemia by stepwise logistic  
46  
47 regression analysis. The multivariable model showed that age, waist circumference,  
48  
49 eGFR, BUN, excessive drinking and presence of fatty liver were associated with  
50  
51 increased prevalence of hyperuricemia in both genders. Elevated serum levels of  
52  
53 AST, total cholesterol, HDL-C and LDL-C were associated with increased prevalence  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 of hyperuricemia in males. Elevated diastolic blood pressure, ALT, and triglyceride  
5  
6 were associated with increased prevalence of hyperuricemia in females (Table 3).  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in non-obese Chinese adults. We found that the prevalence of hyperuricemia was 9.4% in non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, which is lower than that previously reported in general population in East Asia<sup>10,19</sup>, which included both non-obese and obese individuals as a whole, not separately. We found that among non-obese individuals, the overall prevalence of hyperuricemia in men was higher than that in women. However, the prevalence of hyperuricemia increased greatly in women older than 50 years. This phenomenon was also found in other studies<sup>20,21</sup>. This is primarily attributable to sex hormone effects on renal urate transport. It was reported that estrogen affected serum uric acid level through renal clearance, secretion and reabsorption. Young adult women have lower serum urate level than young adult men, but the onset of menopause is associated with increased serum urate level<sup>22</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>23,24</sup>. One possible reason was that we excluded patients undergoing uric acid-lowering treatment in our study. Nowadays, as the prevalence of gout increases

1  
2  
3  
4 significantly with age, number of patients taking uric acid-lowering treatment is also  
5  
6 on the rise as age grows, which may lead to a bias in our research.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with risk of  
12  
13 NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with increased risk of incident hyperuricemia<sup>8</sup>. In this study, we identified  
16  
17 fatty liver as a factor associated with hyperuricemia in non-obese population. Our  
18  
19 results suggested that the interaction between hyperuricemia and metabolic disorders  
20  
21 should also be paid attention to in non-obese population, to prevent further  
22  
23 progression to deteriorated metabolic status.  
24  
25  
26  
27  
28

29  
30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>25</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>26</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and the risk was higher than the relative risk  
39  
40 in those with metabolically healthy obesity (MHO)<sup>27</sup>. It is not rare to find that  
41  
42 MUHNW individuals have a worse prognosis of diabetes than MHO individuals<sup>28</sup>. In  
43  
44 this study, we found that the prevalence of hyperuricemia increased significantly in  
45  
46 MUHNW participants compared with that in MHNW participants. This phenomenon  
47  
48 was more obvious in women. This reminds us that we should pay more attention to  
49  
50 serum uric acid level in MUHNW individuals. As they are more likely to suffer from  
51  
52 hyperuricemia, early intervention in uric acid level may benefit these patients by  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 protecting them from developing further metabolic disorders.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and that  
9  
10 of fatty liver disease in non-obese hyperuricemic participants were higher than those  
11  
12 in hyperuricemia-free controls. This indicated that hyperuricemia in non-obese people  
13  
14 is also accompanied by multiple metabolic disorders. Studies have reported  
15  
16 hyperuricemia as a cause of metabolic syndrome. Our previous studies also found that  
17  
18 hyperuricemia could promote the occurrence and development of NAFLD, and uric  
19  
20 acid-lowering treatment could alleviate NAFLD. Therefore, non-obese hyperuricemic  
21  
22 individuals also need active intervention in uric acid level to reduce the risk of  
23  
24 comorbid metabolic disorders.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged in this study. First, it is a single-center  
33  
34 cross-sectional study. Our sample size may be insufficient to represent the entire  
35  
36 Chinese adult population, and further multi-center cohort studies are needed. Second,  
37  
38 in our study, patients currently undergoing uric acid treatment were excluded, which  
39  
40 may cause a certain bias in the prevalence of the disease. In our research, some factors  
41  
42 related to uric acid were not included, such as gout, renal disease, and treatment with  
43  
44 diuretics, etc. Third, dietary information was not collected, though dietary intake  
45  
46 could be a cofactor associated with hyperuricemia. Some studies have shown that  
47  
48 fructose-enriched food and drink could increase serum UA levels<sup>29</sup>. Meanwhile, this  
49  
50 study diagnosed non-obese participants by the BMI but did not include waist  
51  
52 circumference and waist-to-hip ratio. Some central obese patients could be mixed in  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 non-obese participants.  
5

6       In conclusion, our cross-sectional study showed that the prevalence of  
7  
8  
9 hyperuricemia was 9.4% in non-obese Chinese adults. The prevalence of  
10  
11 hyperuricemia increased significantly in MUHNW participants compared with  
12  
13 MHNW participants. Hyperuricemia in non-obese people was also accompanied by  
14  
15 multiple metabolic disorders. Therefore, clinicians need to pay attention to serum uric  
16  
17 acid level in non-obese patients, especially in metabolically unhealthy individuals.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Fundings**

This work was supported by Key Research and Development Program of Zhejiang Province (No. 2020C03033), National Natural Science Foundation of China (Nos. 81722009, and 81770573), and Health Science and Technology Plan Project of Zhejiang Province (No. 2021437856).

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author Contributions:**

Conceived and designed the experiment: X.C.F. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.Y.W. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

## **Data Availability Statement**

Data are available upon reasonable request

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
13. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
14. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
15. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
16. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.
17. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
18. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection,

- 1  
2  
3 Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*  
4 2001; 285(19): 2486-97.  
5  
6 19. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general  
7 Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol*  
8 2018; 37(9): 2529-38.  
9  
10 20. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being  
11 African-American, serum urate levels and the risk of developing hyperuricemia: findings from the  
12 Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.  
13  
14 21. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident  
15 hyperuricemia during mid-adulthood in African American and white men and women enrolled in the  
16 ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.  
17  
18 22. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum  
19 urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.  
20  
21 23. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in  
22 the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.  
23  
24 24. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the  
25 Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.  
26  
27 25. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the  
28 association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann*  
29 *Hepatol* 2020; 19(4): 359-66.  
30  
31 26. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight  
32 statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination  
33 Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.  
34  
35 27. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4):  
36 558-66.  
37  
38 28. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese  
39 People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the  
40 ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.  
41  
42 29. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and  
43 Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglycerides; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.

Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		P-value	Female		P-value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglycerides; TC: total cholesterol; WC: waist circumference

**Figure Legend**

Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants

Data was expressed as mean with 95% confidence interval (error bars)

Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or metabolically unhealthy participants. Data was expressed as mean±SD. \*\* $p<0.01$ , \*\*\* $p<0.001$ .

For peer review only




Figure 1

121x114mm (300 x 300 DPI)




Figure 2

83x104mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			



Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R2
Article Type:	Original research
Date Submitted by the Author:	06-Oct-2021
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhang, Yuwei; Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Yuwei Zhang<sup>1</sup>,  
12  
13  
14 Chengfu Xu<sup>1,\*</sup>  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20  
21  
22

23  
24  
25 **\*Corresponding author:**  
26

27 Chengfu Xu, M.D.  
28

29  
30 Department of Gastroenterology,  
31

32 The First Affiliated Hospital, Zhejiang University School of Medicine  
33

34  
35 79 Qingchun Road, Hangzhou 310003, China  
36

37  
38 Tel: 0086-571-87236863  
39

40  
41 E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn)  
42  
43  
44

45  
46 # Jinghua Wang and Yishu Chen contributed equally to this work.  
47  
48  
49

50  
51 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
52

53  
54 Nonalcoholic fatty liver disease  
55  
56  
57  
58  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Cross-sectional study

**Setting:** A large general hospital that can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in non-obese Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women older than 50 years old. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Hyperuricemic participants showed a higher prevalence of metabolic syndrome and fatty liver disease than hyperuricemia-free participants. Age, waist circumference,

1  
2  
3  
4 eGFR, blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10

11 Non-obese hyperuricemic participants also showed multiple metabolic disorders.  
12

13  
14 Clinicians should pay attention to serum uric acid level in the non-obese population,  
15  
16 especially in metabolically unhealthy individuals.  
17  
18

### 19 20 21 22 **Strengths and limitations of this study** 23

24 This study included a large sample size of participants (more than 5000 adults), which  
25  
26 made our findings more convincing.  
27  
28

29 This is the first study that has evaluated the prevalence of hyperuricemia among  
30  
31 non-obese adults in China.  
32  
33

34 A multivariate logistic model was used to correct selection biases by adjusting for  
35  
36 potential confounders.  
37  
38

39 It is a single-center cross-sectional study, and further multi-center cohort studies are  
40  
41 needed.  
42  
43

44 Patients currently undergoing uric acid treatment were excluded, which might cause a  
45  
46 certain bias in the prevalence of hyperuricemia in this study.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder that is commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is also associated with other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and regions. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than that of NHANES 1988–1994<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan, China suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. The findings above all call for more attention on the health problem of hyperuricemia from a metabolic perspective.

Many metabolism-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglycerides, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglycerides to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid level, whereas serum HDL-C level was significantly inversely associated<sup>12</sup>. Juraschek *et al.* found

1  
2  
3  
4 that individuals with uncontrolled blood pressure and additional cardiovascular  
5  
6 disease risk factors had a 4-fold or greater prevalence of hyperuricemia<sup>13</sup>.  
7  
8

9 It is generally believed that obesity is closely related to metabolism-related  
10  
11 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
12  
13 Recently, more and more studies have shifted their attention to metabolic disorders in  
14  
15 the non-obese population. Some studies showed that the non-obese population could  
16  
17 also present a high prevalence of NAFLD. For example, as we previously reported,  
18  
19 the prevalence of NAFLD in a non-obese Chinese population was 7.3%<sup>14</sup>. A study  
20  
21 from Japan warned that more than 60% of Japanese diabetic subjects are non-obese<sup>15</sup>.  
22  
23 The findings suggest that it be important to assess metabolic abnormalities in  
24  
25 non-obese individuals. So far, there has still been a paucity of studies on  
26  
27 hyperuricemia in the non-obese population.  
28  
29  
30  
31  
32  
33  
34

35 In this study, we conducted a cross-sectional analysis on a non-obese Chinese  
36  
37 population to evaluate the prevalence of hyperuricemia and determine its associated  
38  
39 factors.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Methods

### Study population

We conducted a cross-sectional study on adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. All participants received medical history collection, anthropometric testing, blood examination, and abdominal ultrasound examination. We excluded the following participants: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, a total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study (Figure S1).

### Clinical evaluations

We collected standing height, body weight, waist circumference and blood pressure from all participants. Height and weight were measured while participants were wearing light clothes without shoes. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical parameters. The values were measured by Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol intake

1  
2  
3  
4 included frequency of alcohol consumption (per week) and usual amount per day.

5  
6 Questions about smoking history included daily smoking count and years of smoking.  
7  
8  
9

### 10 11 **Diagnostic criteria and definitions** 12

13  
14 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
15  
16 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
17  
18 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia was  
19  
20 defined as serum uric acid level >420 μmol/L for men or >360 μmol/L for women.  
21  
22 The factor eGFR (estimated glomerular filtration rate) was calculated using the  
23  
24 modified MDRD formula<sup>16</sup>.  
25  
26  
27  
28

29  
30 All individuals included in the study underwent abdominal ultrasound  
31  
32 examination, which was performed by trained ultrasonographers with a Toshiba  
33  
34 Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
35  
36 blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis  
37  
38 of fatty liver were based on those suggested by the Chinese Liver Disease  
39  
40 Association<sup>17</sup>.  
41  
42  
43  
44

45  
46 Metabolic syndrome was defined by the modified National Cholesterol  
47  
48 Education Program Adult Treatment Panel III report<sup>18</sup>. Participants diagnosed with  
49  
50 metabolic syndrome must have three or more of the following factors: (1) central  
51  
52 obesity, defined as waist circumference >102 cm for men or >88 cm for women; (2)  
53  
54 raised serum triglyceride level, defined as triglycerides ≥ 1.7 mmol/L or specific  
55  
56 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
57  
58  
59  
60

1  
2  
3  
4 cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated blood  
5  
6 pressure, defined as systolic blood pressure  $\geq$ 130 mmHg or diastolic blood pressure  
7  
8  $\geq$ 85 mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
9  
10 blood sugar, defined as fasting blood sugar  $\geq$ 6.1 mmol/L, or previously diagnosed  
11  
12 type 2 diabetes. Metabolically unhealthy participants were defined as those who met  
13  
14 the criteria of metabolic syndrome.  
15  
16  
17  
18  
19  
20  
21

### 22 **Statistical analysis**

23  
24 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
25  
26 Continuous variables were presented as mean and 95% confidence interval (CI) and  
27  
28 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
29  
30 variables were compared using the  $\chi^2$  test. A stepwise logistic regression analysis was  
31  
32 performed to examine the relationship between hyperuricemia and anthropometric or  
33  
34 biochemical variables (probability to enter = 0.05 and probability to remove = 0.10).  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
A *P* value <0.05 (two-tailed) was considered statistically significant.

### 45 **Ethics**

46  
47  
48 All participants were verbally informed of the study's aim and procedures, and gave  
49  
50 voluntary consent. The subject information was anonymized at collection and prior to  
51  
52 analysis. All methods were performed in accordance with the approved guidelines.

53  
54  
55  
56  
57  
58  
59  
60  
The study was approved by Clinical Research Ethics Committee of The First  
Affiliated Hospital, Zhejiang University School of Medicine (No.2021015).

## Patient and Public Involvement

Patients or the public were not involved in the design, or conduct, or report, or dissemination plan of our research.

For peer review only

## Results

### Prevalence of hyperuricemia in the non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4% (16.3% in males and 4.6% in females). In non-obese males, the prevalence of hyperuricemia was stable before the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased before the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants had greater BMI (22.33 (22.19–22.47) versus 21.87 (21.80–21.94)  $\text{kg/m}^2$ ,  $p < 0.001$  in males; 21.64 (21.36–21.92) versus 20.94 (20.88–21.00)  $\text{kg/m}^2$ ,  $p < 0.001$  in females) and waist circumference (83.1 (82.6–83.6) versus 81.3 (81.1–81.5) cm,  $p < 0.001$  in males; 76.6 (75.5–77.7) versus 74.0 (73.8–74.2) cm,  $p < 0.001$  in females), higher diastolic blood pressure (77.2 (76.1–78.3) versus 75.6 (75.1–76.1) mmHg,  $p = 0.006$  in males; 73.9 (72.1–75.7) versus 69.2 (68.8–69.6) mmHg,  $p < 0.001$  in females), and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT) (26.5 (24.7–28.4) versus 21.4 (20.6–22.3) U/L,  $p < 0.001$  in males; 23.2 (18.4–28.0) versus 15.2 (14.9–15.6) U/L,  $p = 0.001$  in females), aspartate aminotransferase (AST) (22.5

(21.6 – 23.5) versus 20.6 (20.1 – 21.0) U/L,  $p=0.001$  in males; 23.1 (20.5 – 25.7) versus 18.4 (18.1 – 18.6) U/L,  $p=0.001$  in females), gamma–glutamyl transpeptidase (GGT) (41.6 (37.7 – 45.6) versus 30.1 (29.1 – 32.9) U/L,  $p<0.001$  in males; 22.9 (19.5 – 26.3) versus 16.8 (16.2 – 17.5) U/L,  $p<0.001$  in females), blood urea nitrogen (BUN) (5.37 (5.21 – 5.53) versus 5.12 (5.07 – 5.17) mmol/L,  $p=0.003$  in males; 5.07 (4.84 – 5.30) versus 4.55 (4.51 – 4.59) mmol/L,  $p<0.001$  in females), and creatinine (86.5 (84.6 – 88.4) versus 81.2 (80.6 – 81.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in males; 63.8 (62.2 – 65.4) versus 59.5 (59.2 – 59.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in females) than hyperuricemia-free participants.

### **Association of hyperuricemia with metabolic disorders in the non-obese population**

We classified all the non-obese participants into metabolically healthy normal weight (MHNW) group and metabolically unhealthy normal weight (MUHNW) group, according to their metabolic status. We found that MUHNW participants had a significantly higher prevalence of hyperuricemia than MHNW participants. In detail, the prevalence of hyperuricemia increased from 15.6% in MHNW participants to 26.7% in MUHNW participants in males ( $p<0.001$ ). Similarly, the prevalence of hyperuricemia increased from 4.1% in MHNW participants to 16.3% in MUHNW participants in females ( $p<0.001$ ) (Figure 2).

We also analyzed the prevalence of metabolic disorders in non-obese individuals with or without hyperuricemia. We found that the prevalence of metabolic syndrome

1  
2  
3  
4 (male 10.2%, female 16%) were significantly higher in hyperuricemic participants  
5  
6 than in hyperuricemia-free participants (male 5.4%, female 4%;  $p < 0.001$  in both  
7  
8 genders). We also found that the prevalence of fatty liver disease (male 30.4%, female  
9  
10 20.5%) were significantly higher in hyperuricemic participants than in  
11  
12 hyperuricemia-free participants (male 13.8%, female 6.4%;  $p < 0.001$  in both genders).  
13  
14 Male hyperuricemic participants had a higher prevalence of raised triglyceride level  
15  
16 and reduced HDL-C than hyperuricemia-free participants. Female hyperuricemic  
17  
18 participants had a higher prevalence of raised triglyceride level, reduced HDL-C,  
19  
20 elevated blood pressure, and raised fasting blood sugar than hyperuricemia-free  
21  
22 participants (Table 2). However, the prevalence of diabetes was not different between  
23  
24 the two groups (Table 2).  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Factors associated with hyperuricemia among the non-obese population**

36  
37 We analyzed the factors associated with hyperuricemia by stepwise logistic  
38  
39 regression analysis. The multivariable model showed that greater waist circumference  
40  
41 values (1.057 (1.030–1.084) in males and 1.038 (1.006–1.071) in females), elevated  
42  
43 BUN levels (1.114 (1.014–1.223) in males and 1.308 (1.137–1.505) in females),  
44  
45 excessive drinking (1.501 (1.097–2.055) in males and 3.562 (1.408–9.011) in  
46  
47 females) and presence of fatty liver (1.959 (1.472–2.607) in males and 1.900 (1.164–  
48  
49 3.102) in females) were associated with an increased prevalence of hyperuricemia in  
50  
51 both genders. Greater age (0.961 (0.950–0.972) in males and 0.958 (0.939–0.977) in  
52  
53 females) and elevated eGFR levels (0.973 (0.965–0.980) in males and 0.976 (0.966–  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 0.985) in females) were associated with a decreased prevalence of hyperuricemia in  
5  
6 both genders. Elevated serum levels of AST (1.014 (1.004–1.024)) and total  
7  
8 cholesterol (2.717 (1.921–3.843)) were associated with an increased prevalence of  
9  
10 hyperuricemia in males. Elevated serum levels of HDL-C (0.378 (0.240–0.594)) and  
11  
12 LDL-C (0.386 (0.256–0.583)) were associated with a decreased prevalence of  
13  
14 hyperuricemia in males. Elevated diastolic blood pressure (1.033 (1.016–1.050)),  
15  
16 higher ALT (1.023 (1.013–1.033)) and triglyceride (1.423 (1.199–1.690)) levels were  
17  
18 associated with an increased prevalence of hyperuricemia in females (Table 3).  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in a non-obese Chinese population. We found that the prevalence of hyperuricemia was 9.4% in the non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, lower than the value previously reported in the general population in East Asia<sup>10,19</sup>, which included both non-obese and obese individuals as a whole, not separately. We found that in the non-obese individuals, the overall prevalence of hyperuricemia was higher in men than in women. However, the prevalence of hyperuricemia increased greatly in women older than 50, which can also be corroborated by other studies<sup>20,21</sup>. This is primarily attributable to the sex hormone effects on renal urate transport. It has been reported that estrogen affects serum uric acid level through renal clearance, secretion and reabsorption. Young adult women have a lower serum urate level than young adult men, while the onset of menopause is associated with an increased serum urate level<sup>22</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>23,24</sup>. One possible reason was that we had excluded patients undergoing uric acid-lowering treatment in our study. Nowadays, as the prevalence of gout increases

1  
2  
3  
4 significantly with age, the number of patients taking uric acid-lowering treatment is  
5  
6 also on the rise as age grows, which may lead to a bias in our research<sup>25, 26</sup>.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with the risk  
12  
13 of NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with an increased risk of incident hyperuricemia<sup>8</sup>. In this study, we  
16  
17 identified fatty liver as a factor associated with hyperuricemia in the non-obese  
18  
19 population. Our results suggested that the interaction between hyperuricemia and  
20  
21 metabolic disorders should also be paid attention to in the non-obese population, to  
22  
23 prevent further progression to deteriorated metabolic status.  
24  
25  
26  
27  
28  
29

30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>27</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>28</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and higher than the relative risk in those with  
39  
40 metabolically healthy obesity (MHO)<sup>29</sup>. It is not rare to find that MUHNW  
41  
42 individuals have a worse prognosis of diabetes than MHO individuals<sup>30</sup>. In this study,  
43  
44 we found that the prevalence of hyperuricemia increased significantly in MUHNW  
45  
46 participants compared with that in MHNW participants. This phenomenon was more  
47  
48 obvious in women, which reminds us that we should pay more attention to serum uric  
49  
50 acid level in MUHNW individuals. As they are more likely to suffer from  
51  
52  
53  
54  
55  
56  
57  
58  
59 hyperuricemia, early intervention in uric acid level may benefit these patients by  
60

1  
2  
3  
4 protecting them from developing further metabolic disorders<sup>31</sup>.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and that  
9  
10 of fatty liver disease in non-obese hyperuricemic participants were higher than those  
11  
12 in hyperuricemia-free controls. This indicated that hyperuricemia in the non-obese  
13  
14 population is also accompanied by multiple metabolic disorders. Studies have  
15  
16 reported hyperuricemia as a cause of metabolic syndrome. Our previous studies also  
17  
18 found that hyperuricemia could promote the occurrence and development of NAFLD,  
19  
20 and uric acid-lowering treatment could alleviate NAFLD<sup>8</sup>. Therefore, non-obese  
21  
22 hyperuricemic individuals also need active intervention in uric acid level to reduce the  
23  
24 risk of comorbid metabolic disorders<sup>32</sup>.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged in this study. First, it is a single-center  
33  
34 cross-sectional study. Our sample size may be insufficient to represent the entire  
35  
36 Chinese adult population, and further multi-center cohort studies are needed. Second,  
37  
38 in our study, patients currently undergoing uric acid treatment were excluded, which  
39  
40 may cause a certain bias in the prevalence of the disease. In our research, some factors  
41  
42 related to uric acid were not included, such as gout, renal disease, and treatment with  
43  
44 diuretics, etc. Third, dietary information was not collected, though dietary intake  
45  
46 could be a cofactor associated with hyperuricemia. Some studies have shown that  
47  
48 fructose-enriched food and drink could increase serum UA levels<sup>33</sup>. Meanwhile, this  
49  
50 study defined the non-obese participants by BMI without including waist  
51  
52 circumference or waist-to-hip ratio. Some central obese patients could be mixed in the  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 non-obese participants.  
5

6       In conclusion, our cross-sectional study showed that the prevalence of  
7  
8  
9 hyperuricemia was 9.4% in the non-obese Chinese population. The prevalence of  
10  
11 hyperuricemia increased significantly in MUHNW participants compared with  
12  
13 MHNW participants. Hyperuricemia in non-obese people was also accompanied by  
14  
15 multiple metabolic disorders. Therefore, clinicians need to pay attention to serum uric  
16  
17 acid level in non-obese patients, especially in metabolically unhealthy individuals.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Fundings**

This work was supported by Key Research and Development Program of Zhejiang Province (No. 2020C03033), National Natural Science Foundation of China (Nos. 81722009, and 81770573), and Health Science and Technology Plan Project of Zhejiang Province (No. 2021KY147).

**Conflicts of interest**

The authors declare no conflicts of interest.

**Author Contributions:**

Conceived and designed the experiment: X.C.F. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.Y.W. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

**Data Availability Statement**

Data are available upon reasonable request

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
13. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
14. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
15. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
16. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.
17. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
18. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection,

- 1  
2  
3 Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA*  
4 2001; 285(19): 2486-97.
- 5  
6 19. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general  
7 Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol*  
8 2018; 37(9): 2529-38.
- 9  
10 20. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being  
11 African-American, serum urate levels and the risk of developing hyperuricemia: findings from the  
12 Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
- 13  
14 21. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident  
15 hyperuricemia during mid-adulthood in African American and white men and women enrolled in the  
16 ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
- 17  
18 22. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum  
19 urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
- 20  
21 23. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in  
22 the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
- 23  
24 24. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the  
25 Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.
- 26  
27 25. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment  
28 patterns and risk factors. *Nat Rev Rheumatol* 2020; 16(7): 380-90.
- 29  
30 26. Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of  
31 Care in a National Australian General Practice Population. *J Rheumatol* 2015; 42(9): 1702-7.
- 32  
33 27. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the  
34 association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann*  
35 *Hepatol* 2020; 19(4): 359-66.
- 36  
37 28. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight  
38 statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination  
39 Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
- 40  
41 29. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4):  
42 558-66.
- 43  
44 30. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese  
45 People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the  
46 ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
- 47  
48 31. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular,  
49 metabolic and kidney disease. *Eur J Intern Med* 2020; 80: 1-11.
- 50  
51 32. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering  
52 treatments: implications for optimal treatment of chronic hyperuricemia. *Vasc Health Risk Manag*  
53 2017; 13: 23-28.
- 54  
55 33. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and  
56 Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).
- 57  
58  
59  
60

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglycerides; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.



Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		<i>P</i> -value	Female		<i>P</i> -value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglycerides; TC: total cholesterol; WC: waist circumference

**Figure Legend**

Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants

Data was expressed as mean with 95% confidence interval (error bars)

Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or

metabolically unhealthy participants. Data was expressed as mean  $\pm$  SD. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

For peer review only




Figure 1

121x114mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

83x104mm (300 x 300 DPI)




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R3
Article Type:	Original research
Date Submitted by the Author:	26-Jan-2022
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhai, Haoliang; Haining Branch of the First Affiliated Hospital, Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Haoliang Zhai<sup>2,\*</sup>,  
12  
13  
14 Chengfu Xu<sup>1,2,\*</sup>  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20

21  
22 <sup>2</sup> Department of Gastroenterology, Haining Branch of the First Affiliated Hospital,  
23  
24 Zhejiang University School of Medicine, Haining 314400, China  
25  
26

27  
28  
29  
30 **\*Corresponding author:**  
31

32  
33 Chengfu Xu, M.D., Department of Gastroenterology, The First Affiliated Hospital,  
34  
35 Zhejiang University School of Medicine. 79 Qingchun Road, Hangzhou 310003,  
36  
37 China, Tel: 0086-571-87236863, E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn).  
38

39  
40 Haoliang Zhai, Department of Gastroenterology, Haining Branch of the First  
41  
42 Affiliated Hospital, Zhejiang University School of Medicine. 79 Qingchun Road,  
43  
44 Hangzhou 314400, China, Tel: 0086-573-89230531, E-mail: [inzaghi1004@sina.com](mailto:inzaghi1004@sina.com).  
45  
46  
47

48  
49  
50  
51 # Jinghua Wang and Yishu Chen contributed equally to this work.  
52

53  
54  
55  
56 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
57  
58 Nonalcoholic fatty liver disease  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Cross-sectional study

**Setting:** A large general hospital that can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in non-obese Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women over 50 years old. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Hyperuricemic participants showed a higher prevalence of metabolic syndrome and fatty liver disease than normoureemic participants. Age, waist circumference, eGFR,

1  
2  
3  
4 blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10  
11 Non-obese hyperuricemic participants also showed multiple metabolic disorders. We  
12  
13 suggest that clinicians pay attention to serum uric acid level in non-obese patients.  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study** 20

21  
22 This study included a large sample size of participants (more than 5000 adults), which  
23  
24 made our findings more convincing.  
25

26  
27 This is the first study that has evaluated the prevalence of hyperuricemia among  
28  
29 non-obese adults in China.  
30

31  
32 A multivariate logistic model was used to correct selection biases by adjusting for  
33  
34 potential confounders.  
35

36  
37 It is a single-center cross-sectional study, and further multi-center cohort studies are  
38  
39 needed.  
40

41  
42 Patients currently undergoing urate-lowering treatment were excluded, which might  
43  
44 cause a selection bias in the prevalence of hyperuricemia in this study.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is also associated with other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and regions. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than that of NHANES 1988–1994<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan, China suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. The findings above may call for more attention on the health problem of hyperuricemia from a metabolic perspective, yet entailing further verification across populations.

Many metabolism-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglyceride, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglyceride to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid level, whereas

1  
2  
3  
4 serum HDL-C level was significantly inversely associated<sup>12</sup>. Juraschek *et al.* found  
5  
6 that individuals with uncontrolled blood pressure and additional cardiovascular  
7  
8 disease risk factors had a 4-fold or higher prevalence of hyperuricemia<sup>13</sup>.  
9  
10

11 It is generally believed that obesity is closely associated with metabolism-related  
12  
13 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
14  
15 Recently, more and more studies have shifted their attention to metabolic disorders in  
16  
17 the non-obese population. Some studies showed that the non-obese population could  
18  
19 also present a high prevalence of NAFLD. For example, as we previously reported,  
20  
21 the prevalence of NAFLD in a non-obese Chinese population was 7.3%<sup>14</sup>. A study  
22  
23 from Japan warned that more than 60% of Japanese diabetic subjects are non-obese<sup>15</sup>.  
24  
25 The findings suggest that it be important to assess metabolic abnormalities in  
26  
27 non-obese individuals. So far, there has still been a paucity of studies on  
28  
29 hyperuricemia in the non-obese population.  
30  
31  
32  
33  
34  
35  
36

37 In this study, we conducted a cross-sectional analysis on a non-obese Chinese  
38  
39 population to evaluate the prevalence of hyperuricemia and determine its associated  
40  
41 factors.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Study population

We conducted a cross-sectional study on adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. All participants received medical history collection, anthropometric testing, blood examination, and abdominal ultrasound examination. We excluded the following participants: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, a total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study (Figure S1).

### Clinical evaluations

We collected standing height, body weight, waist circumference and blood pressure from all participants. Height and weight were measured while participants were wearing light clothes without shoes. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical parameters. The values were measured by a Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol



1  
2  
3  
4 intake included frequency of alcohol consumption (per week) and usual amount per  
5  
6 day. Questions about smoking history included daily smoking count and years of  
7  
8 smoking.  
9  
10

### 11 12 13 14 **Diagnostic criteria and definitions**

15  
16  
17 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
18  
19 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
20  
21 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia was  
22  
23 defined as serum uric acid level >420 μmol/L for men or >360 μmol/L for women<sup>8, 16,</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
17. The factor eGFR (estimated glomerular filtration rate) was calculated using the  
modified MDRD formula<sup>18</sup>.

All individuals included in the study underwent abdominal ultrasound  
examination, which was performed by trained ultrasonographers with a Toshiba  
Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis  
of fatty liver were based on those suggested by the Chinese Liver Disease  
Association<sup>19</sup>.

Metabolic syndrome was defined according to the modified National Cholesterol  
Education Program Adult Treatment Panel III report<sup>20</sup>. Participants diagnosed with  
metabolic syndrome must have three or more of the following factors: (1) central  
obesity, defined as waist circumference >102 cm for men or >88 cm for women; (2)  
raised serum triglyceride level, defined as triglyceride ≥ 1.7 mmol/L or specific

1  
2  
3  
4 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
5  
6 cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated blood  
7  
8 pressure, defined as systolic blood pressure  $\geq$ 130 mmHg or diastolic blood pressure  
9  
10  $\geq$ 85 mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
11  
12 blood sugar, defined as fasting blood sugar  $\geq$ 6.1 mmol/L, or previously diagnosed  
13  
14 type 2 diabetes. Metabolically unhealthy participants were defined as those who met  
15  
16 the criteria of metabolic syndrome.  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Statistical analyses**

26  
27 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
28  
29 Continuous variables were presented as mean and 95% confidence interval (CI) and  
30  
31 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
32  
33 variables were compared using the  $\chi^2$  test. A stepwise logistic regression analysis was  
34  
35 performed to examine the relationship between hyperuricemia and anthropometric or  
36  
37 biochemical variables (probability to enter = 0.05 and probability to remove = 0.10).  
38  
39 A *P* value <0.05 (two-tailed) was considered statistically significant.  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Ethics**

49  
50 All participants were verbally informed of the study's aim and procedures, and gave  
51  
52 voluntary consent. The subject information was anonymized at collection prior to  
53  
54 analysis. All methods were performed in accordance with the approved guidelines.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The study was approved by the Clinical Research Ethics Committee of the First  
5  
6 Affiliated Hospital, Zhejiang University School of Medicine (No.2021015).  
7  
8  
9  
10

### 11 **Patient and public involvement**

12  
13  
14 Patients or the public were not involved in the design, conduct, report, or  
15  
16 dissemination of our research.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### Prevalence of hyperuricemia in the non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4% (16.3% in males and 4.6% in females). In non-obese males, the prevalence of hyperuricemia was stable before the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased with age before the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants showed greater BMI (22.33 (22.19–22.47) versus 21.87 (21.80–21.94)  $\text{kg/m}^2$ ,  $p < 0.001$  in males; 21.64 (21.36–21.92) versus 20.94 (20.88–21.00)  $\text{kg/m}^2$ ,  $p < 0.001$  in females) and waist circumference (83.1 (82.6–83.6) versus 81.3 (81.1–81.5) cm,  $p < 0.001$  in males; 76.6 (75.5–77.7) versus 74.0 (73.8–74.2) cm,  $p < 0.001$  in females), higher diastolic blood pressure (77.2 (76.1–78.3) versus 75.6 (75.1–76.1) mmHg,  $p = 0.006$  in males; 73.9 (72.1–75.7) versus 69.2 (68.8–69.6) mmHg,  $p < 0.001$  in females), and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT) (26.5 (24.7–28.4) versus 21.4 (20.6–22.3) U/L,  $p < 0.001$  in males; 23.2 (18.4–28.0) versus 15.2 (14.9–15.6) U/L,  $p = 0.001$  in females), aspartate aminotransferase (AST)

1  
2  
3  
4 (22.5 (21.6 – 23.5) versus 20.6 (20.1 – 21.0) U/L,  $p=0.001$  in males; 23.1 (20.5 – 25.7)  
5  
6  
7 versus 18.4 (18.1 – 18.6) U/L,  $p=0.001$  in females), gamma–glutamyl transpeptidase  
8  
9 (GGT) (41.6 (37.7 – 45.6) versus 30.1 (29.1 – 32.9) U/L,  $p<0.001$  in males; 22.9  
10  
11 (19.5 – 26.3) versus 16.8 (16.2 – 17.5) U/L,  $p<0.001$  in females), blood urea nitrogen  
12  
13 (BUN) (5.37 (5.21 – 5.53) versus 5.12 (5.07 – 5.17) mmol/L,  $p=0.003$  in males; 5.07  
14  
15 (4.84 – 5.30) versus 4.55 (4.51 – 4.59) mmol/L,  $p<0.001$  in females), and creatinine  
16  
17 (86.5 (84.6 – 88.4) versus 81.2 (80.6 – 81.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in males; 63.8 (62.2 –  
18  
19 65.4) versus 59.5 (59.2 – 59.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in females) than normouremic  
20  
21  
22  
23  
24  
25 participants.

### 26 27 28 29 30 **Association of hyperuricemia with metabolic disorders in the non-obese** 31 32 **population**

33  
34  
35 We classified all the non-obese participants into metabolically healthy normal  
36  
37 weight (MHNW) group and metabolically unhealthy normal weight (MUHNW)  
38  
39 group, according to their metabolic status. We found that MUHNW participants had a  
40  
41 significantly higher prevalence of hyperuricemia than MHNW participants. In detail,  
42  
43 the prevalence of hyperuricemia increased from 15.6% in MHNW participants to  
44  
45 26.7% in MUHNW participants in males ( $p<0.001$ ). Similarly, the prevalence of  
46  
47 hyperuricemia increased from 4.1% in MHNW participants to 16.3% in MUHNW  
48  
49  
50  
51 participants in females ( $p<0.001$ ) (Figure 2).  
52  
53  
54

55  
56 We also analyzed the prevalence of metabolic disorders in non-obese individuals  
57  
58 with or without hyperuricemia. We found that the prevalence of metabolic syndrome  
59  
60

1  
2  
3  
4 were significantly higher in hyperuricemic participants (male 10.2%, female 16%)  
5  
6 than in normoureemic participants (male 5.4%, female 4%;  $p < 0.001$  in both genders).  
7  
8

9 We also found that the prevalence of fatty liver disease were significantly higher in  
10  
11 hyperuricemic participants (male 30.4%, female 20.5%) than in normoureemic  
12  
13 participants (male 13.8%, female 6.4%;  $p < 0.001$  in both genders). Male  
14  
15 hyperuricemic participants had a higher prevalence of raised triglyceride level and  
16  
17 reduced HDL-C than normoureemic participants. Female hyperuricemic participants  
18  
19 had a higher prevalence of raised triglyceride level, reduced HDL-C, elevated blood  
20  
21 pressure, and raised fasting blood sugar than normoureemic participants (Table 2).  
22  
23  
24  
25  
26  
27 However, the prevalence of diabetes was not different between the two groups (Table  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Factors associated with hyperuricemia among the non-obese population**

We analyzed the factors associated with hyperuricemia by stepwise logistic regression analysis. The multivariable model showed that greater waist circumference values (1.057 (1.030–1.084) (the data was expressed as OR (95%CI) , the same below) in males and 1.038 (1.006–1.071) in females), elevated BUN levels (1.114 (1.014–1.223) in males and 1.308 (1.137–1.505) in females), excessive drinking (1.501 (1.097–2.055) in males and 3.562 (1.408–9.011) in females) and presence of fatty liver (1.959 (1.472–2.607) in males and 1.900 (1.164–3.102) in females) were associated with an increased prevalence of hyperuricemia in both genders. Greater age (0.961 (0.950–0.972) in males and 0.958 (0.939–0.977) in females) and elevated

1  
2  
3  
4 eGFR levels (0.973 (0.965–0.980) in males and 0.976 (0.966–0.985) in females) were  
5  
6 associated with a decreased prevalence of hyperuricemia in both genders. Elevated  
7  
8 serum levels of AST (1.014 (1.004–1.024)) and total cholesterol (2.717 (1.921–  
9  
10 3.843)) were associated with an increased prevalence of hyperuricemia in males.  
11  
12 Elevated serum levels of HDL-C (0.378 (0.240–0.594)) and LDL-C (0.386 (0.256–  
13  
14 0.583)) were associated with a decreased prevalence of hyperuricemia in males.  
15  
16 Elevated diastolic blood pressure (1.033 (1.016–1.050)), higher ALT (1.023 (1.013–  
17  
18 1.033)) and triglyceride (1.423 (1.199–1.690)) levels were associated with an  
19  
20 increased prevalence of hyperuricemia in females (Table 3).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in a non-obese Chinese population. We found that the prevalence of hyperuricemia was 9.4% in the non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, lower than the value previously reported in the general population in East Asia<sup>10, 21</sup>, which included both non-obese and obese individuals as a whole, not separately. We found that in the non-obese individuals, the overall prevalence of hyperuricemia was higher in men than in women. However, the prevalence of hyperuricemia increased greatly in women older than 50, which could be corroborated by other studies<sup>22, 23</sup>. This is primarily attributable to the sex hormone effects on renal urate transport. It has been reported that estrogen affects serum uric acid level through renal clearance, secretion and reabsorption. Young adult women have a lower serum urate level than young adult men, while the onset of menopause is associated with an increased serum urate level<sup>24</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>25, 26</sup>. One possible reason was that we have excluded patients undergoing urate-lowering treatment in our study. Nowadays, as the prevalence of gout increases



1  
2  
3  
4 significantly with age, the number of patients taking urate-lowering treatment is also  
5  
6 on the rise as age grows, which may lead to a selection bias in our research<sup>27, 28</sup>.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with the risk  
12  
13 of NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with an increased risk of incident hyperuricemia<sup>8</sup>. In this study, we  
16  
17 identified fatty liver as a factor associated with hyperuricemia in the non-obese  
18  
19 population. Our results suggested that the interaction between hyperuricemia and  
20  
21 metabolic disorders should also be paid attention to in the non-obese population, to  
22  
23 prevent further progression to deteriorated metabolic status.  
24  
25  
26  
27  
28  
29

30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>29</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>30</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and higher than the relative risk in those with  
39  
40 metabolically healthy obesity (MHO)<sup>31</sup>. It is not rare to find that MUHNW  
41  
42 individuals have a worse prognosis of diabetes than MHO individuals<sup>32</sup>. In this study,  
43  
44 we found that the prevalence of hyperuricemia increased significantly in MUHNW  
45  
46 participants compared with that in MHNW participants. This phenomenon was more  
47  
48 obvious in women, which implied that we could pay more attention to serum uric acid  
49  
50 level in MUHNW individuals. As they are more likely to suffer from hyperuricemia,  
51  
52 early intervention in uric acid level may benefit these patients by protecting them  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from developing further metabolic disorders<sup>33</sup>.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and of  
9  
10 fatty liver disease in non-obese hyperuricemic participants were higher than those in  
11  
12 normoureemic controls. This indicated that hyperuricemia in the non-obese population  
13  
14 could also be accompanied by multiple metabolic disorders. Studies have reported  
15  
16 hyperuricemia as a cause of metabolic syndrome<sup>7</sup>. Our previous studies also found  
17  
18 that hyperuricemia could promote the occurrence and development of NAFLD, and  
19  
20 urate-lowering treatment could alleviate NAFLD<sup>8</sup>. Therefore, non-obese  
21  
22 hyperuricemic individuals may also need active intervention in uric acid level to  
23  
24 reduce the risk of comorbid metabolic disorders<sup>34</sup>.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged in this study. First, it is a single-center  
33  
34 cross-sectional study. Our sample size may be insufficient to represent the entire  
35  
36 Chinese adult population, and further multi-center cohort studies are needed. Second,  
37  
38 in our study, patients currently undergoing urate-lowering treatment were excluded,  
39  
40 which might cause a selection bias in the prevalence of hyperuricemia. In our  
41  
42 research, some factors related to uric acid were not included, such as gout, renal  
43  
44 disease, and treatment with diuretics, etc. Third, dietary information was not  
45  
46 collected, though dietary intake could be a cofactor associated with hyperuricemia.  
47  
48 Some studies have shown that fructose-enriched food and drink could increase serum  
49  
50 UA levels<sup>35</sup>. Meanwhile, this study defined the non-obese participants by BMI  
51  
52 without including waist circumference or waist-to-hip ratio. Some central obese  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients could be mixed in the non-obese participants.  
5

6         In conclusion, our cross-sectional study showed that the prevalence of  
7  
8  
9 hyperuricemia was 9.4% in the non-obese Chinese population. The prevalence of  
10  
11 hyperuricemia increased significantly in MUHNW participants compared with  
12  
13 MHNW participants. Hyperuricemia in non-obese people could also be accompanied  
14  
15 by multiple metabolic disorders. Therefore, we suggest that clinicians pay attention to  
16  
17 serum uric acid level in non-obese patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Fundings**

This work was supported by Health Science and Technology Plan Project of Zhejiang Province (No. 2021KY147, and 2021KY1129), Key Research and Development Program of Zhejiang Province (No. 2020C03033), and National Natural Science Foundation of China (Nos. 82070585, and 81770573).

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author Contributions:**

Conceived and designed the experiment: X.C.F. and Z.H.L. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.H.L. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

## **Data Availability Statement**

Data are available upon reasonable request.

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
13. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
14. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
15. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
16. Huang YF, Yang KH, Chen SH, et al. [Practice guideline for patients with hyperuricemia/gout]. *Zhonghua Nei Ke Za Zhi* 2020; 59(7): 519-27.
17. Zhang Y, Nie FQ, Huang XB, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. *BMC Cardiovasc Disord* 2022; 22(1): 2.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.

19. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
20. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19): 2486-97.
21. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol* 2018; 37(9): 2529-38.
22. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
23. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
24. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
25. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
26. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.
27. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* 2020; 16(7): 380-90.
28. Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. *J Rheumatol* 2015; 42(9): 1702-7.
29. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol* 2020; 19(4): 359-66.
30. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
31. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4): 558-66.
32. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
33. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. *Eur J Intern Med* 2020; 80: 1-11.
34. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. *Vasc Health Risk Manag* 2017; 13: 23-28.
35. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglyceride; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.



Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		<i>P</i> -value	Female		<i>P</i> -value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglyceride; TC: total cholesterol; WC: waist circumference

**Figure Legend**

Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants

Data was expressed as mean with 95% confidence interval (error bars)

Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or

metabolically unhealthy participants. Data was expressed as mean  $\pm$  SD. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

For peer review only




Figure 1

121x114mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2

83x104mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R4
Article Type:	Original research
Date Submitted by the Author:	06-Feb-2022
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhai, Haoliang; Haining Branch of the First Affiliated Hospital, Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Haoliang Zhai<sup>2,\*</sup>,  
12  
13 Chengfu Xu<sup>1,2,\*</sup>  
14  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20  
21

22  
23 <sup>2</sup> Department of Gastroenterology, Haining Branch of the First Affiliated Hospital,  
24  
25 Zhejiang University School of Medicine, Haining 314400, China  
26  
27

28  
29  
30 **\*Corresponding author:**  
31

32  
33 Chengfu Xu, M.D., Department of Gastroenterology, The First Affiliated Hospital,  
34  
35 Zhejiang University School of Medicine. 79 Qingchun Road, Hangzhou 310003,  
36  
37 China, Tel: 0086-571-87236863, E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn).  
38  
39

40  
41 Haoliang Zhai, Department of Gastroenterology, Haining Branch of the First  
42  
43 Affiliated Hospital, Zhejiang University School of Medicine. 79 Qingchun Road,  
44  
45 Hangzhou 314400, China, Tel: 0086-573-89230531, E-mail: [inzaghi1004@sina.com](mailto:inzaghi1004@sina.com).  
46  
47

48  
49  
50  
51 # Jinghua Wang and Yishu Chen contributed equally to this work.  
52  
53

54  
55  
56 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
57  
58 Nonalcoholic fatty liver disease  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Cross-sectional study

**Setting:** A large general hospital that can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in non-obese Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women over 50 years old. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Hyperuricemic participants showed a higher prevalence of metabolic syndrome and fatty liver disease than normoureemic participants. Age, waist circumference, eGFR,

1  
2  
3  
4 blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10  
11 Non-obese hyperuricemic participants also showed multiple metabolic disorders. We  
12  
13 suggest that clinicians pay attention to serum uric acid level in non-obese patients.  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study** 20

21  
22 This study included a large sample size of participants (more than 5000 adults), which  
23  
24 made our findings more convincing.  
25

26  
27 This is the first study that has evaluated the prevalence of hyperuricemia among  
28  
29 non-obese adults in China.  
30

31  
32 A multivariate logistic model was used to correct selection biases by adjusting for  
33  
34 potential confounders.  
35

36  
37 It is a single-center cross-sectional study, and further multi-center cohort studies are  
38  
39 needed.  
40

41  
42 Patients currently undergoing urate-lowering treatment were excluded, which might  
43  
44 cause a selection bias in the prevalence of hyperuricemia in this study.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is also associated with other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and regions. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than that of NHANES 1988–1994<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan, China suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. The findings above may call for more attention on the health problem of hyperuricemia from a metabolic perspective, yet entailing further verification across populations.

Many metabolism-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglyceride, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglyceride to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid level, whereas

1  
2  
3  
4 serum HDL-C level was significantly inversely associated<sup>12</sup>. Juraschek *et al.* found  
5  
6 that individuals with uncontrolled blood pressure and additional cardiovascular  
7  
8 disease risk factors had a 4-fold or higher prevalence of hyperuricemia<sup>13</sup>.  
9  
10

11 It is generally believed that obesity is closely associated with metabolism-related  
12  
13 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
14  
15 Recently, more and more studies have shifted their attention to metabolic disorders in  
16  
17 the non-obese population. Some studies showed that the non-obese population could  
18  
19 also present a high prevalence of NAFLD. For example, as we previously reported,  
20  
21 the prevalence of NAFLD in a non-obese Chinese population was 7.3%<sup>14</sup>. A study  
22  
23 from Japan warned that more than 60% of Japanese diabetic subjects are non-obese<sup>15</sup>.  
24  
25 The findings suggest that it be important to assess metabolic abnormalities in  
26  
27 non-obese individuals. So far, there has still been a paucity of studies on  
28  
29 hyperuricemia in the non-obese population.  
30  
31  
32  
33  
34  
35  
36

37 In this study, we conducted a cross-sectional analysis on a non-obese Chinese  
38  
39 population to evaluate the prevalence of hyperuricemia and determine its associated  
40  
41 factors.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Study population

We conducted a cross-sectional study on adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. All participants received medical history collection, anthropometric testing, blood examination, and abdominal ultrasound examination. We excluded the following participants: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, a total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study (Figure S1).

### Clinical evaluations

We collected standing height, body weight, waist circumference and blood pressure from all participants. Height and weight were measured while participants were wearing light clothes without shoes. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical parameters. The values were measured by a Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol



1  
2  
3  
4 intake included frequency of alcohol consumption (per week) and usual amount per  
5  
6 day. Questions about smoking history included daily smoking count and years of  
7  
8 smoking.  
9  
10

### 11 12 13 14 **Diagnostic criteria and definitions**

15  
16  
17 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
18  
19 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
20  
21 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia was  
22  
23 defined as serum uric acid level >420 μmol/L for men or >360 μmol/L for women<sup>8, 16,</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
17. The factor eGFR (estimated glomerular filtration rate) was calculated using the  
modified MDRD formula<sup>18</sup>.

All individuals included in the study underwent abdominal ultrasound  
examination, which was performed by trained ultrasonographers with a Toshiba  
Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
blinded to the study design and the clinical data. The criteria for ultrasonic diagnosis  
of fatty liver were based on those suggested by the Chinese Liver Disease  
Association<sup>19</sup>.

Metabolic syndrome was defined according to the modified National Cholesterol  
Education Program Adult Treatment Panel III report<sup>20</sup>. Participants diagnosed with  
metabolic syndrome must have three or more of the following factors: (1) central  
obesity, defined as waist circumference >102 cm for men or >88 cm for women; (2)  
raised serum triglyceride level, defined as triglyceride ≥ 1.7 mmol/L or specific

1  
2  
3  
4 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
5  
6 cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated blood  
7  
8 pressure, defined as systolic blood pressure  $\geq 130$  mmHg or diastolic blood pressure  
9  
10  $\geq 85$  mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
11  
12 blood sugar, defined as fasting blood sugar  $\geq 6.1$  mmol/L, or previously diagnosed  
13  
14 type 2 diabetes. Metabolically unhealthy participants were defined as those who met  
15  
16 the criteria of metabolic syndrome.  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Statistical analyses**

26  
27 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
28  
29 Continuous variables were presented as mean and 95% confidence interval (CI) and  
30  
31 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
32  
33 variables were compared using the  $\chi^2$  test. A stepwise logistic regression analysis was  
34  
35 performed to examine the relationship between hyperuricemia and anthropometric or  
36  
37 biochemical variables (probability to enter = 0.05 and probability to remove = 0.10).  
38  
39 A *P* value <0.05 (two-tailed) was considered statistically significant.  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Ethics**

49  
50 All participants were verbally informed of the study's aim and procedures, and gave  
51  
52 voluntary consent. The subject information was anonymized at collection prior to  
53  
54 analysis. All methods were performed in accordance with the approved guidelines.  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The study was approved by the Clinical Research Ethics Committee of the First  
5  
6 Affiliated Hospital, Zhejiang University School of Medicine (No.2021015).  
7  
8  
9  
10

### 11 **Patient and public involvement**

12  
13  
14 Patients or the public were not involved in the design, conduct, report, or  
15  
16 dissemination of our research.  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### Prevalence of hyperuricemia in the non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4% (16.3% in males and 4.6% in females). In non-obese males, the prevalence of hyperuricemia was stable before the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased with age before the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants showed greater BMI (22.33 (22.19–22.47) versus 21.87 (21.80–21.94)  $\text{kg/m}^2$ ,  $p < 0.001$  in males; 21.64 (21.36–21.92) versus 20.94 (20.88–21.00)  $\text{kg/m}^2$ ,  $p < 0.001$  in females) and waist circumference (83.1 (82.6–83.6) versus 81.3 (81.1–81.5) cm,  $p < 0.001$  in males; 76.6 (75.5–77.7) versus 74.0 (73.8–74.2) cm,  $p < 0.001$  in females), higher diastolic blood pressure (77.2 (76.1–78.3) versus 75.6 (75.1–76.1) mmHg,  $p = 0.006$  in males; 73.9 (72.1–75.7) versus 69.2 (68.8–69.6) mmHg,  $p < 0.001$  in females), and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT) (26.5 (24.7–28.4) versus 21.4 (20.6–22.3) U/L,  $p < 0.001$  in males; 23.2 (18.4–28.0) versus 15.2 (14.9–15.6) U/L,  $p = 0.001$  in females), aspartate aminotransferase (AST)

1  
2  
3  
4 (22.5 (21.6 – 23.5) versus 20.6 (20.1 – 21.0) U/L,  $p=0.001$  in males; 23.1 (20.5 – 25.7)  
5  
6  
7 versus 18.4 (18.1 – 18.6) U/L,  $p=0.001$  in females), gamma–glutamyl transpeptidase  
8  
9 (GGT) (41.6 (37.7 – 45.6) versus 30.1 (29.1 – 32.9) U/L,  $p<0.001$  in males; 22.9  
10  
11 (19.5 – 26.3) versus 16.8 (16.2 – 17.5) U/L,  $p<0.001$  in females), blood urea nitrogen  
12  
13 (BUN) (5.37 (5.21 – 5.53) versus 5.12 (5.07 – 5.17) mmol/L,  $p=0.003$  in males; 5.07  
14  
15 (4.84 – 5.30) versus 4.55 (4.51 – 4.59) mmol/L,  $p<0.001$  in females), and creatinine  
16  
17 (86.5 (84.6 – 88.4) versus 81.2 (80.6 – 81.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in males; 63.8 (62.2 –  
18  
19 65.4) versus 59.5 (59.2 – 59.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in females) than normoemic  
20  
21  
22  
23  
24  
25 participants.

### 26 27 28 29 30 **Association of hyperuricemia with metabolic disorders in the non-obese** 31 32 **population**

33  
34  
35 We classified all the non-obese participants into metabolically healthy normal  
36  
37 weight (MHNW) group and metabolically unhealthy normal weight (MUHNW)  
38  
39 group, according to their metabolic status. We found that MUHNW participants had a  
40  
41 significantly higher prevalence of hyperuricemia than MHNW participants. In detail,  
42  
43 the prevalence of hyperuricemia increased from 15.6% in MHNW participants to  
44  
45 26.7% in MUHNW participants in males ( $p<0.001$ ). Similarly, the prevalence of  
46  
47 hyperuricemia increased from 4.1% in MHNW participants to 16.3% in MUHNW  
48  
49  
50  
51 participants in females ( $p<0.001$ ) (Figure 2).  
52  
53  
54

55  
56 We also analyzed the prevalence of metabolic disorders in non-obese individuals  
57  
58 with or without hyperuricemia. We found that the prevalence of metabolic syndrome  
59  
60

1  
2  
3  
4 were significantly higher in hyperuricemic participants (male 10.2%, female 16%)  
5  
6 than in normoureemic participants (male 5.4%, female 4%;  $p < 0.001$  in both genders).  
7  
8

9 We also found that the prevalence of fatty liver disease were significantly higher in  
10  
11 hyperuricemic participants (male 30.4%, female 20.5%) than in normoureemic  
12  
13 participants (male 13.8%, female 6.4%;  $p < 0.001$  in both genders). Male  
14  
15 hyperuricemic participants had a higher prevalence of raised triglyceride level and  
16  
17 reduced HDL-C than normoureemic participants. Female hyperuricemic participants  
18  
19 had a higher prevalence of raised triglyceride level, reduced HDL-C, elevated blood  
20  
21 pressure, and raised fasting blood sugar than normoureemic participants (Table 2).  
22  
23  
24  
25  
26  
27 However, the prevalence of diabetes was not different between the two groups (Table  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Factors associated with hyperuricemia among the non-obese population**

We analyzed the factors associated with hyperuricemia by stepwise logistic regression analysis. The multivariable model showed that greater waist circumference values (1.057 (1.030–1.084) (the data was expressed as OR (95%CI) , the same below) in males and 1.038 (1.006–1.071) in females), elevated BUN levels (1.114 (1.014–1.223) in males and 1.308 (1.137–1.505) in females), excessive drinking (1.501 (1.097–2.055) in males and 3.562 (1.408–9.011) in females) and presence of fatty liver (1.959 (1.472–2.607) in males and 1.900 (1.164–3.102) in females) were associated with an increased prevalence of hyperuricemia in both genders. Greater age (0.961 (0.950–0.972) in males and 0.958 (0.939–0.977) in females) and elevated

1  
2  
3  
4 eGFR levels (0.973 (0.965–0.980) in males and 0.976 (0.966–0.985) in females) were  
5  
6 associated with a decreased prevalence of hyperuricemia in both genders. Elevated  
7  
8 serum levels of AST (1.014 (1.004–1.024)) and total cholesterol (2.717 (1.921–  
9  
10 3.843)) were associated with an increased prevalence of hyperuricemia in males.  
11  
12 Elevated serum levels of HDL-C (0.378 (0.240–0.594)) and LDL-C (0.386 (0.256–  
13  
14 0.583)) were associated with a decreased prevalence of hyperuricemia in males.  
15  
16 Elevated diastolic blood pressure (1.033 (1.016–1.050)), higher ALT (1.023 (1.013–  
17  
18 1.033)) and triglyceride (1.423 (1.199–1.690)) levels were associated with an  
19  
20 increased prevalence of hyperuricemia in females (Table 3).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in a non-obese Chinese population. We found that the prevalence of hyperuricemia was 9.4% in the non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, lower than the value previously reported in the general population in East Asia<sup>10, 21</sup>, which included both non-obese and obese individuals as a whole, not separately. We found that in the non-obese individuals, the overall prevalence of hyperuricemia was higher in men than in women. However, the prevalence of hyperuricemia increased greatly in women older than 50, which could be corroborated by other studies<sup>22, 23</sup>. This is primarily attributable to the sex hormone effects on renal urate transport. It has been reported that estrogen affects serum uric acid level through renal clearance, secretion and reabsorption. Young adult women have a lower serum urate level than young adult men, while the onset of menopause is associated with an increased serum urate level<sup>24</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>25, 26</sup>. One possible reason was that we have excluded patients undergoing urate-lowering treatment in our study. Nowadays, as the prevalence of gout increases



1  
2  
3  
4 significantly with age, the number of patients taking urate-lowering treatment is also  
5  
6 on the rise as age grows, which may lead to a selection bias in our research<sup>27, 28</sup>.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with the risk  
12  
13 of NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with an increased risk of incident hyperuricemia<sup>8</sup>. In this study, we  
16  
17 identified fatty liver as a factor associated with hyperuricemia in the non-obese  
18  
19 population. Our results suggested that the interaction between hyperuricemia and  
20  
21 metabolic disorders should also be paid attention to in the non-obese population, to  
22  
23 prevent further progression to deteriorated metabolic status.  
24  
25  
26  
27  
28  
29

30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>29</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>30</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and higher than the relative risk in those with  
39  
40 metabolically healthy obesity (MHO)<sup>31</sup>. It is not rare to find that MUHNW  
41  
42 individuals have a worse prognosis of diabetes than MHO individuals<sup>32</sup>. In this study,  
43  
44 we found that the prevalence of hyperuricemia increased significantly in MUHNW  
45  
46 participants compared with that in MHNW participants. This phenomenon was more  
47  
48 obvious in women, which implied that we could pay more attention to serum uric acid  
49  
50 level in MUHNW individuals. As they are more likely to suffer from hyperuricemia,  
51  
52 early intervention in uric acid level may benefit these patients by protecting them  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from developing further metabolic disorders<sup>33</sup>.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and of  
9  
10 fatty liver disease in non-obese hyperuricemic participants were higher than those in  
11  
12 normoureemic controls. This indicated that hyperuricemia in the non-obese population  
13  
14 could also be accompanied by multiple metabolic disorders. Studies have reported  
15  
16 hyperuricemia as a cause of metabolic syndrome<sup>7</sup>. Our previous studies also found  
17  
18 that hyperuricemia could promote the occurrence and development of NAFLD, and  
19  
20 urate-lowering treatment could alleviate NAFLD<sup>8</sup>. Therefore, non-obese  
21  
22 hyperuricemic individuals may also need active intervention in uric acid level to  
23  
24 reduce the risk of comorbid metabolic disorders<sup>34</sup>.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged in this study. First, it is a single-center  
33  
34 cross-sectional study. Our sample size may be insufficient to represent the entire  
35  
36 Chinese adult population, and further multi-center cohort studies are needed. Second,  
37  
38 in our study, patients currently undergoing urate-lowering treatment were excluded,  
39  
40 which might cause a selection bias in the prevalence of hyperuricemia. In our  
41  
42 research, some factors related to uric acid were not included, such as gout, renal  
43  
44 disease, and treatment with diuretics, etc. Third, dietary information was not  
45  
46 collected, though dietary intake could be a cofactor associated with hyperuricemia.  
47  
48 Some studies have shown that fructose-enriched food and drink could increase serum  
49  
50 UA levels<sup>35</sup>. Meanwhile, this study defined the non-obese participants by BMI  
51  
52 without including waist circumference or waist-to-hip ratio. Some central obese  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients could be mixed in the non-obese participants.  
5

6         In conclusion, our cross-sectional study showed that the prevalence of  
7  
8  
9 hyperuricemia was 9.4% in the non-obese Chinese population. The prevalence of  
10  
11 hyperuricemia increased significantly in MUHNW participants compared with  
12  
13 MHNW participants. Hyperuricemia in non-obese people could also be accompanied  
14  
15 by multiple metabolic disorders. Therefore, we suggest that clinicians pay attention to  
16  
17 serum uric acid level in non-obese patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Fundings**

This work was supported by Health Science and Technology Plan Project of Zhejiang Province (No. 2021KY147, and 2021KY1129), Key Research and Development Program of Zhejiang Province (No. 2020C03033), and National Natural Science Foundation of China (Nos. 82070585, and 81770573).

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author Contributions:**

Conceived and designed the experiment: X.C.F. and Z.H.L. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.H.L. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

## **Data Availability Statement**

Data are available upon reasonable request.

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
13. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
14. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
15. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
16. Huang YF, Yang KH, Chen SH, et al. [Practice guideline for patients with hyperuricemia/gout]. *Zhonghua Nei Ke Za Zhi* 2020; 59(7): 519-27.
17. Zhang Y, Nie FQ, Huang XB, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. *BMC Cardiovasc Disord* 2022; 22(1): 2.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.

19. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
20. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19): 2486-97.
21. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol* 2018; 37(9): 2529-38.
22. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
23. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
24. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
25. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
26. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.
27. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* 2020; 16(7): 380-90.
28. Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. *J Rheumatol* 2015; 42(9): 1702-7.
29. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol* 2020; 19(4): 359-66.
30. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
31. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4): 558-66.
32. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
33. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. *Eur J Intern Med* 2020; 80: 1-11.
34. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. *Vasc Health Risk Manag* 2017; 13: 23-28.
35. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglyceride; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.



Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		<i>P</i> -value	Female		<i>P</i> -value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglyceride; TC: total cholesterol; WC: waist circumference

1  
2  
3  
4 **Figure Legend**  
5

6 Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants  
7

8  
9 Data was expressed as mean with 95% confidence interval (error bars)  
10

11 Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or  
12

13  
14 metabolically unhealthy participants. Data was expressed as mean  $\pm$  SD. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1

121x114mm (300 x 300 DPI)




Figure 2

83x104mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R5
Article Type:	Original research
Date Submitted by the Author:	14-Feb-2022
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhai, Haoliang; Haining Branch of the First Affiliated Hospital, Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Haoliang Zhai<sup>2,\*</sup>,  
12  
13  
14 Chengfu Xu<sup>1,2,\*</sup>  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20

21  
22 <sup>2</sup> Department of Gastroenterology, Haining Branch of the First Affiliated Hospital,  
23  
24 Zhejiang University School of Medicine, Haining 314400, China  
25  
26

27  
28  
29  
30 **\*Corresponding author:**  
31

32  
33 Chengfu Xu, M.D., Department of Gastroenterology, The First Affiliated Hospital,  
34  
35 Zhejiang University School of Medicine. 79 Qingchun Road, Hangzhou 310003,  
36  
37 China, Tel: 0086-571-87236863, E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn).  
38

39  
40 Haoliang Zhai, Department of Gastroenterology, Haining Branch of the First  
41  
42 Affiliated Hospital, Zhejiang University School of Medicine. 79 Qingchun Road,  
43  
44 Hangzhou 314400, China, Tel: 0086-573-89230531, E-mail: [inzaghi1004@sina.com](mailto:inzaghi1004@sina.com).  
45  
46  
47

48  
49  
50  
51 # Jinghua Wang and Yishu Chen contributed equally to this work.  
52

53  
54  
55  
56 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
57  
58 Nonalcoholic fatty liver disease  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Retrospective cross-sectional study

**Setting:** A large general hospital that can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in non-obese Chinese adults.

**Results:** Of the 5731 non-obese participants enrolled, 538 (9.4%) were diagnosed as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia increased greatly in women over 50 years old. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Hyperuricemic participants showed a higher prevalence of metabolic syndrome and fatty liver disease than normoureemic participants. Age, waist circumference, eGFR,

1  
2  
3  
4 blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10  
11 Non-obese hyperuricemic participants also showed multiple metabolic disorders. We  
12  
13 suggest that clinicians pay attention to serum uric acid level in non-obese patients.  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study**

20  
21  
22 This study included a large sample size of participants (more than 5000 adults), which  
23  
24 made our findings more convincing.  
25

26  
27 This is the first study that has evaluated the prevalence of hyperuricemia among  
28  
29 non-obese adults in China.  
30

31  
32 A multivariate logistic model was used to correct selection biases by adjusting for  
33  
34 potential confounders.  
35

36  
37 It is a single-center cross-sectional study, and further multi-center cohort studies are  
38  
39 needed.  
40

41  
42 Patients currently undergoing urate-lowering treatment were excluded, which might  
43  
44 cause a selection bias in the prevalence of hyperuricemia in this study.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is also associated with other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and regions. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than that of NHANES 1988–1994<sup>9</sup>. A recent meta-analysis reported that the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan, China suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. The findings above may call for more attention on the health problem of hyperuricemia from a metabolic perspective, yet entailing further verification across populations.

Many metabolism-related indicators are independent risk factors for hyperuricemia. A study from the United States reported that serum levels of triglyceride, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and ratio of triglyceride to high-density lipoprotein cholesterol (HDL-C) were strongly positively associated with serum uric acid level, whereas

1  
2  
3  
4 serum HDL-C level was significantly inversely associated<sup>12</sup>. Juraschek *et al.* found  
5  
6 that individuals with uncontrolled blood pressure and additional cardiovascular  
7  
8 disease risk factors had a 4-fold or higher prevalence of hyperuricemia<sup>13</sup>.  
9  
10

11 It is generally believed that obesity is closely associated with metabolism-related  
12  
13 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
14  
15 Recently, more and more studies have shifted their attention to metabolic disorders in  
16  
17 the non-obese population. Some studies showed that the non-obese population could  
18  
19 also present a high prevalence of NAFLD. For example, as we previously reported,  
20  
21 the prevalence of NAFLD in a non-obese Chinese population was 7.3%<sup>14</sup>. A study  
22  
23 from Japan warned that more than 60% of Japanese diabetic subjects are non-obese<sup>15</sup>.  
24  
25 The findings suggest that it be important to assess metabolic abnormalities in  
26  
27 non-obese individuals. So far, there has still been a paucity of studies on  
28  
29 hyperuricemia in the non-obese population.  
30  
31  
32  
33  
34  
35  
36

37 In this study, we conducted a retrospective cross-sectional analysis on a non-obese  
38  
39 Chinese population to evaluate the prevalence of hyperuricemia and determine its  
40  
41 associated factors.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Study population

The study population of this cross-sectional study was adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. All participants received medical history collection, anthropometric testing, blood examination, and abdominal ultrasound examination. The exclusion criteria of the study were as follows: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had a BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, a total of 5731 participants (2349 men and 3382 women) were qualified for the cross-sectional study (Figure S1).

### Clinical evaluations

Standing height, body weight, waist circumference and blood pressure were collected from all participants. Height and weight were measured while participants were wearing light clothes without shoes. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Blood pressure was measured using a standard protocol. Fasting serum samples were obtained for the analysis of biochemical parameters. The values were measured by a Hitachi 7600 clinical analyzer (Hitachi, Tokyo, Japan) using standard methods. Questions about alcohol



1  
2  
3  
4 intake included frequency of alcohol consumption (per week) and usual amount per  
5  
6 day. Questions about smoking history included daily smoking count and years of  
7  
8 smoking.  
9  
10

### 11 12 13 14 **Diagnostic criteria and definitions** 15

16  
17 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
18  
19 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
20  
21 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia was  
22  
23 defined as serum uric acid level >420 μmol/L for men or >360 μmol/L for women<sup>8, 16,</sup>  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
17. The factor eGFR (estimated glomerular filtration rate) was calculated using the  
modified MDRD formula<sup>18</sup>.

All individuals included in the study underwent abdominal ultrasound  
examination, which was performed by trained ultrasonographers with a Toshiba  
Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The ultrasonographers were  
blinded to clinical assessments and laboratory results. The criteria for ultrasonic  
diagnosis of fatty liver were based on those suggested by the Chinese Liver Disease  
Association<sup>19</sup>.

Metabolic syndrome was defined according to the modified National Cholesterol  
Education Program Adult Treatment Panel III report<sup>20</sup>. Participants diagnosed with  
metabolic syndrome must have three or more of the following factors: (1) central  
obesity, defined as waist circumference >102 cm for men or >88 cm for women; (2)  
raised serum triglyceride level, defined as triglyceride ≥ 1.7 mmol/L or specific

1  
2  
3  
4 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
5  
6 cholesterol <1.03 mmol/L for men or <1.29 mmol/L for women; (4) elevated blood  
7  
8 pressure, defined as systolic blood pressure  $\geq 130$  mmHg or diastolic blood pressure  
9  
10  $\geq 85$  mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
11  
12 blood sugar, defined as fasting blood sugar  $\geq 6.1$  mmol/L, or previously diagnosed  
13  
14 type 2 diabetes. Metabolically unhealthy participants were defined as those who met  
15  
16 the criteria of metabolic syndrome.  
17  
18  
19  
20  
21  
22  
23  
24

### 25 **Statistical analyses**

26  
27 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
28  
29 Continuous variables were presented as mean and 95% confidence interval (CI) and  
30  
31 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
32  
33 variables were compared using the  $\chi^2$  test. A stepwise logistic regression analysis was  
34  
35 performed to examine the relationship between hyperuricemia and anthropometric or  
36  
37 biochemical variables (probability to enter = 0.05 and probability to remove = 0.10).  
38  
39 A *P* value <0.05 (two-tailed) was considered statistically significant.  
40  
41  
42  
43  
44  
45  
46  
47

### 48 **Ethics**

49  
50 During the health checkup, the participants were informed of the potential use of their  
51  
52 checkups data for future research and that the subject information would be  
53  
54 anonymized at collection prior to analysis. All methods were performed in accordance  
55  
56 with the approved guidelines. The study was approved by the Clinical Research  
57  
58  
59  
60

1  
2  
3  
4 Ethics Committee of the First Affiliated Hospital, Zhejiang University School of  
5  
6 Medicine (No.2021015). Written consent was not required because of the  
7  
8 retrospective observational design of the study.  
9  
10

### 11 12 13 14 **Patient and public involvement** 15

16  
17 Patients or the public were not involved in the design, conduct, report, or  
18  
19 dissemination of our research.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### Prevalence of hyperuricemia in the non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4% (16.3% in males and 4.6% in females). In non-obese males, the prevalence of hyperuricemia was stable before the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased with age before the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants showed greater BMI (22.33 (22.19–22.47) versus 21.87 (21.80–21.94)  $\text{kg/m}^2$ ,  $p < 0.001$  in males; 21.64 (21.36–21.92) versus 20.94 (20.88–21.00)  $\text{kg/m}^2$ ,  $p < 0.001$  in females) and waist circumference (83.1 (82.6–83.6) versus 81.3 (81.1–81.5) cm,  $p < 0.001$  in males; 76.6 (75.5–77.7) versus 74.0 (73.8–74.2) cm,  $p < 0.001$  in females), higher diastolic blood pressure (77.2 (76.1–78.3) versus 75.6 (75.1–76.1) mmHg,  $p = 0.006$  in males; 73.9 (72.1–75.7) versus 69.2 (68.8–69.6) mmHg,  $p < 0.001$  in females), and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT) (26.5 (24.7–28.4) versus 21.4 (20.6–22.3) U/L,  $p < 0.001$  in males; 23.2 (18.4–28.0) versus 15.2 (14.9–15.6) U/L,  $p = 0.001$  in females), aspartate aminotransferase (AST)

1  
2  
3  
4 (22.5 (21.6 – 23.5) versus 20.6 (20.1 – 21.0) U/L,  $p=0.001$  in males; 23.1 (20.5 – 25.7)  
5  
6  
7 versus 18.4 (18.1 – 18.6) U/L,  $p=0.001$  in females), gamma–glutamyl transpeptidase  
8  
9 (GGT) (41.6 (37.7 – 45.6) versus 30.1 (29.1 – 32.9) U/L,  $p<0.001$  in males; 22.9  
10  
11 (19.5 – 26.3) versus 16.8 (16.2 – 17.5) U/L,  $p<0.001$  in females), blood urea nitrogen  
12  
13 (BUN) (5.37 (5.21 – 5.53) versus 5.12 (5.07 – 5.17) mmol/L,  $p=0.003$  in males; 5.07  
14  
15 (4.84 – 5.30) versus 4.55 (4.51 – 4.59) mmol/L,  $p<0.001$  in females), and creatinine  
16  
17 (86.5 (84.6 – 88.4) versus 81.2 (80.6 – 81.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in males; 63.8 (62.2 –  
18  
19 65.4) versus 59.5 (59.2 – 59.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in females) than normo-uricemic  
20  
21  
22  
23  
24  
25 participants.

### 26 27 28 29 30 **Association of hyperuricemia with metabolic disorders in the non-obese** 31 32 **population**

33  
34  
35 We classified all the non-obese participants into metabolically healthy normal  
36  
37 weight (MHNW) group and metabolically unhealthy normal weight (MUHNW)  
38  
39 group, according to their metabolic status. We found that MUHNW participants had a  
40  
41 significantly higher prevalence of hyperuricemia than MHNW participants. In detail,  
42  
43 the prevalence of hyperuricemia increased from 15.6% in MHNW participants to  
44  
45 26.7% in MUHNW participants in males ( $p<0.001$ ). Similarly, the prevalence of  
46  
47 hyperuricemia increased from 4.1% in MHNW participants to 16.3% in MUHNW  
48  
49  
50  
51 participants in females ( $p<0.001$ ) (Figure 2).  
52  
53  
54

55  
56 We also analyzed the prevalence of metabolic disorders in non-obese individuals  
57  
58 with or without hyperuricemia. We found that the prevalence of metabolic syndrome  
59  
60

1  
2  
3  
4 were significantly higher in hyperuricemic participants (male 10.2%, female 16%)  
5  
6 than in normoureemic participants (male 5.4%, female 4%;  $p < 0.001$  in both genders).  
7  
8

9 We also found that the prevalence of fatty liver disease were significantly higher in  
10  
11 hyperuricemic participants (male 30.4%, female 20.5%) than in normoureemic  
12  
13 participants (male 13.8%, female 6.4%;  $p < 0.001$  in both genders). Male  
14  
15 hyperuricemic participants had a higher prevalence of raised triglyceride level and  
16  
17 reduced HDL-C than normoureemic participants. Female hyperuricemic participants  
18  
19 had a higher prevalence of raised triglyceride level, reduced HDL-C, elevated blood  
20  
21 pressure, and raised fasting blood sugar than normoureemic participants (Table 2).  
22  
23  
24  
25  
26  
27 However, the prevalence of diabetes was not different between the two groups (Table  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Factors associated with hyperuricemia among the non-obese population**

We analyzed the factors associated with hyperuricemia by stepwise logistic regression analysis. The multivariable model showed that greater waist circumference values (1.057 (1.030–1.084) (the data was expressed as OR (95%CI) , the same below) in males and 1.038 (1.006–1.071) in females), elevated BUN levels (1.114 (1.014–1.223) in males and 1.308 (1.137–1.505) in females), excessive drinking (1.501 (1.097–2.055) in males and 3.562 (1.408–9.011) in females) and presence of fatty liver (1.959 (1.472–2.607) in males and 1.900 (1.164–3.102) in females) were associated with an increased prevalence of hyperuricemia in both genders. Greater age (0.961 (0.950–0.972) in males and 0.958 (0.939–0.977) in females) and elevated

1  
2  
3  
4 eGFR levels (0.973 (0.965–0.980) in males and 0.976 (0.966–0.985) in females) were  
5  
6 associated with a decreased prevalence of hyperuricemia in both genders. Elevated  
7  
8 serum levels of AST (1.014 (1.004–1.024)) and total cholesterol (2.717 (1.921–  
9  
10 3.843)) were associated with an increased prevalence of hyperuricemia in males.  
11  
12 Elevated serum levels of HDL-C (0.378 (0.240–0.594)) and LDL-C (0.386 (0.256–  
13  
14 0.583)) were associated with a decreased prevalence of hyperuricemia in males.  
15  
16 Elevated diastolic blood pressure (1.033 (1.016–1.050)), higher ALT (1.023 (1.013–  
17  
18 1.033)) and triglyceride (1.423 (1.199–1.690)) levels were associated with an  
19  
20 increased prevalence of hyperuricemia in females (Table 3).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in a non-obese Chinese population. We found that the prevalence of hyperuricemia was 9.4% in the non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, lower than the value previously reported in the general population in East Asia<sup>10, 21</sup>, which included both non-obese and obese individuals as a whole, not separately. We found that in the non-obese individuals, the overall prevalence of hyperuricemia was higher in men than in women. However, the prevalence of hyperuricemia increased greatly in women older than 50, which could be corroborated by other studies<sup>22, 23</sup>. This is primarily attributable to the sex hormone effects on renal urate transport. It has been reported that estrogen affects serum uric acid level through renal clearance, secretion and reabsorption. Young adult women have a lower serum urate level than young adult men, while the onset of menopause is associated with an increased serum urate level<sup>24</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>25, 26</sup>. One possible reason was that we have excluded patients undergoing urate-lowering treatment in our study. Nowadays, as the prevalence of gout increases



1  
2  
3  
4 significantly with age, the number of patients taking urate-lowering treatment is also  
5  
6 on the rise as age grows, which may lead to a selection bias in our research<sup>27, 28</sup>.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with the risk  
12  
13 of NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with an increased risk of incident hyperuricemia<sup>8</sup>. In this study, we  
16  
17 identified fatty liver as a factor associated with hyperuricemia in the non-obese  
18  
19 population. Our results suggested that the interaction between hyperuricemia and  
20  
21 metabolic disorders should also be paid attention to in the non-obese population, to  
22  
23 prevent further progression to deteriorated metabolic status.  
24  
25  
26  
27  
28  
29

30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>29</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>30</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and higher than the relative risk in those with  
39  
40 metabolically healthy obesity (MHO)<sup>31</sup>. It is not rare to find that MUHNW  
41  
42 individuals have a worse prognosis of diabetes than MHO individuals<sup>32</sup>. In this study,  
43  
44 we found that the prevalence of hyperuricemia increased significantly in MUHNW  
45  
46 participants compared with that in MHNW participants. This phenomenon was more  
47  
48 obvious in women, which implied that we could pay more attention to serum uric acid  
49  
50 level in MUHNW individuals. As they are more likely to suffer from hyperuricemia,  
51  
52 early intervention in uric acid level may benefit these patients by protecting them  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from developing further metabolic disorders<sup>33</sup>.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and of  
9  
10 fatty liver disease in non-obese hyperuricemic participants were higher than those in  
11  
12 normoureemic controls. This indicated that hyperuricemia in the non-obese population  
13  
14 could also be accompanied by multiple metabolic disorders. Studies have reported  
15  
16 hyperuricemia as a cause of metabolic syndrome<sup>7</sup>. Our previous studies also found  
17  
18 that hyperuricemia could promote the occurrence and development of NAFLD, and  
19  
20 urate-lowering treatment could alleviate NAFLD<sup>8</sup>. Therefore, non-obese  
21  
22 hyperuricemic individuals may also need active intervention in uric acid level to  
23  
24 reduce the risk of comorbid metabolic disorders<sup>34</sup>.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged in this study. First, it is a single-center  
33  
34 cross-sectional study. Our sample size may be insufficient to represent the entire  
35  
36 Chinese adult population, and further multi-center cohort studies are needed. Second,  
37  
38 in our study, patients currently undergoing urate-lowering treatment were excluded,  
39  
40 which might cause a selection bias in the prevalence of hyperuricemia. In our  
41  
42 research, some factors related to uric acid were not included, such as gout, renal  
43  
44 disease, and treatment with diuretics, etc. Third, dietary information was not  
45  
46 collected, though dietary intake could be a cofactor associated with hyperuricemia.  
47  
48 Some studies have shown that fructose-enriched food and drink could increase serum  
49  
50 UA levels<sup>35</sup>. Meanwhile, this study defined the non-obese participants by BMI  
51  
52 without including waist circumference or waist-to-hip ratio. Some central obese  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 patients could be mixed in the non-obese participants.  
5

6  
7 In conclusion, our retrospective cross-sectional study showed that the prevalence  
8  
9 of hyperuricemia was 9.4% in the non-obese Chinese population. The prevalence of  
10  
11 hyperuricemia increased significantly in MUHNW participants compared with  
12  
13 MHNW participants. Hyperuricemia in non-obese people could also be accompanied  
14  
15 by multiple metabolic disorders. Therefore, we suggest that clinicians pay attention to  
16  
17 serum uric acid level in non-obese patients.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Fundings**

This work was supported by Health Science and Technology Plan Project of Zhejiang Province (No. 2021KY147, and 2021KY1129), Key Research and Development Program of Zhejiang Province (No. 2020C03033), and National Natural Science Foundation of China (Nos. 82070585, and 81770573).

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author Contributions:**

Conceived and designed the experiment: X.C.F. and Z.H.L. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.H.L. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

## **Data Availability Statement**

Data are available upon reasonable request.

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
13. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
14. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
15. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
16. Huang YF, Yang KH, Chen SH, et al. [Practice guideline for patients with hyperuricemia/gout]. *Zhonghua Nei Ke Za Zhi* 2020; 59(7): 519-27.
17. Zhang Y, Nie FQ, Huang XB, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. *BMC Cardiovasc Disord* 2022; 22(1): 2.
18. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.

19. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
20. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19): 2486-97.
21. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol* 2018; 37(9): 2529-38.
22. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
23. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
24. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
25. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
26. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.
27. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* 2020; 16(7): 380-90.
28. Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. *J Rheumatol* 2015; 42(9): 1702-7.
29. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol* 2020; 19(4): 359-66.
30. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
31. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4): 558-66.
32. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
33. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. *Eur J Intern Med* 2020; 80: 1-11.
34. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. *Vasc Health Risk Manag* 2017; 13: 23-28.
35. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglyceride; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.



Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		P-value	Female		P-value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglyceride; TC: total cholesterol; WC: waist circumference

1  
2  
3  
4 **Figure Legend**  
5

6 Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants  
7

8  
9 Data was expressed as mean with 95% confidence interval (error bars)  
10

11 Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or  
12

13  
14 metabolically unhealthy participants. Data was expressed as mean  $\pm$  SD. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1

121x114mm (300 x 300 DPI)




Figure 2

83x104mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).



# BMJ Open

## Prevalence and risk factors of hyperuricemia in non-obese Chinese: a single-center cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-048574.R6
Article Type:	Original research
Date Submitted by the Author:	21-Apr-2022
Complete List of Authors:	Wang, Jinghua; Zhejiang University School of Medicine First Affiliated Hospital, Chen, Yishu; Zhejiang University School of Medicine, Department of Gastroenterology Chen, Shenghui; Zhejiang University School of Medicine, Department of Gastroenterology Wang, Xinyu; Zhejiang University School of Medicine, Department of Gastroenterology Zhai, Haoliang; Haining Branch of the First Affiliated Hospital, Zhejiang University School of Medicine, Department of Gastroenterology Xu, Chengfu; Zhejiang University School of Medicine, Department of Gastroenterology
<b>Primary Subject Heading</b>:	Rheumatology
Secondary Subject Heading:	Public health, Rheumatology, Epidemiology
Keywords:	General endocrinology < DIABETES & ENDOCRINOLOGY, PUBLIC HEALTH, RHEUMATOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Prevalence and risk factors of hyperuricemia in non-obese Chinese: a**  
5  
6 **single-center cross-sectional study**  
7  
8  
9

10  
11 Jinghua Wang<sup>1,#</sup>, Yishu Chen<sup>1,#</sup>, Shenghui Chen<sup>1</sup>, Xinyu Wang<sup>1</sup>, Haoliang Zhai<sup>2,\*</sup>,  
12  
13 Chengfu Xu<sup>1,2,\*</sup>  
14  
15

16  
17 <sup>1</sup> Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University  
18  
19 School of Medicine, Hangzhou 310003, China  
20  
21

22  
23 <sup>2</sup> Department of Gastroenterology, Haining Branch of the First Affiliated Hospital,  
24  
25 Zhejiang University School of Medicine, Haining 314400, China  
26  
27

28  
29  
30 **\*Corresponding author:**  
31

32  
33 Chengfu Xu, M.D., Department of Gastroenterology, The First Affiliated Hospital,  
34  
35 Zhejiang University School of Medicine. 79 Qingchun Road, Hangzhou 310003,  
36  
37 China, Tel: 0086-571-87236863, E-mail: [xiaofu@zju.edu.cn](mailto:xiaofu@zju.edu.cn).  
38  
39

40  
41 Haoliang Zhai, Department of Gastroenterology, Haining Branch of the First  
42  
43 Affiliated Hospital, Zhejiang University School of Medicine. 79 Qingchun Road,  
44  
45 Hangzhou 314400, China, Tel: 0086-573-89230531, E-mail: [inzaghi1004@sina.com](mailto:inzaghi1004@sina.com).  
46  
47

48  
49  
50  
51 # Jinghua Wang and Yishu Chen contributed equally to this work.  
52  
53

54  
55  
56 **Key words:** Hyperuricemia; Non-obese; Risk factor; Cross-sectional study;  
57  
58 Nonalcoholic fatty liver disease  
59  
60

## Abstract

**Objectives:** Hyperuricemia is closely related to metabolic diseases and is receiving increasing attention from all over the world. This study aimed to investigate the prevalence and factors associated with hyperuricemia in non-obese Chinese population.

**Design:** Retrospective cross-sectional study

**Setting:** A large general hospital that can provide health checkups in Hangzhou, China.

**Participants:** A total of 5731 apparently healthy Chinese adults (2349 men and 3382 women) who took their health checkups during the year of 2019. Exclusion criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment.

**Primary and secondary outcome measures:** The prevalence and factors associated with hyperuricemia in non-obese Chinese adults.

**Results:** Of the 5731 non-obese subjects enrolled, 538 (9.4%) were identified as hyperuricemia, specifically 16.3% in men and 4.6% in women. The prevalence of hyperuricemia markedly increased in females aged above 50. The prevalence of hyperuricemia was significantly higher in metabolically unhealthy participants with normal weight than in metabolically healthy participants with normal weight. Hyperuricemic participants showed a higher prevalence of metabolic syndrome and fatty liver disease than normoureemic participants. Age, waist circumference, eGFR,

1  
2  
3  
4 blood urea nitrogen, excessive drinking and fatty liver were associated with  
5  
6 hyperuricemia in both genders.  
7

8  
9 **Conclusion:** The prevalence of hyperuricemia was 9.4% in non-obese Chinese adults.  
10  
11 Non-obese hyperuricemic participants also showed multiple metabolic disorders. We  
12  
13 suggest that clinicians pay attention to serum uric acid level in non-obese patients.  
14  
15  
16

### 17 18 19 **Strengths and limitations of this study** 20

21  
22 This study included a large sample size of participants (more than 5000 adults), which  
23  
24 made our findings more convincing.  
25

26  
27 This is the first study that has evaluated the prevalence of hyperuricemia among  
28  
29 non-obese adults in China.  
30

31  
32 A multivariate logistic model was used to correct selection biases by adjusting for  
33  
34 potential confounders.  
35

36  
37 It is a single-center cross-sectional study, and further multi-center cohort studies are  
38  
39 needed.  
40

41  
42 Patients currently undergoing urate-lowering treatment were excluded, which might  
43  
44 cause a selection bias in the prevalence of hyperuricemia in this study.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Hyperuricemia, defined as elevated uric acid level in blood, is a metabolic disorder commonly recognized to be closely related to gout and CKD<sup>1</sup>. Over the last decade, more and more studies have found that hyperuricemia is also associated with other metabolic diseases, such as obesity, hypertension, dyslipidemia, and nonalcoholic fatty liver disease (NAFLD)<sup>2-6</sup>. Some studies also suggested hyperuricemia as an independent risk factor for metabolic syndrome and non-alcoholic fatty liver disease<sup>7, 8</sup>. Moreover, the prevalence of hyperuricemia varies across populations and regions. In the United States, approximately 21.4% of adults met the criteria for hyperuricemia in the first decade of the 21st century, which was 3.2% higher than the proportion reported by NHANES 1988–1994<sup>9</sup>. According to a recent meta-analysis, the pooled prevalence of hyperuricemia was 13.3% in China<sup>10</sup>. A study from Wuhan, China suggested that the prevalence of hyperuricemia in men rose from 26.1% in 2010 to 34.4% in 2019, and the prevalence of hyperuricemia in women rose from 5.8% in 2010 to 10.1% in 2019<sup>11</sup>. It is reported that the prevalence of hyperuricemia was 18.4% and the incidence of hyperuricemia was 68.58 cases per 1000 person-year of follow-up in Eastern China<sup>12</sup>. The findings above may call for more attention on the health problem of hyperuricemia from a metabolic perspective, yet entailing further verification across populations.

Many metabolism-related indicators are independent risk factors for hyperuricemia. Serum levels of triglyceride, total cholesterol, apolipoprotein-B, and low-density lipoprotein cholesterol (LDL-C), and the ratio of triglyceride to

1  
2  
3  
4 high-density lipoprotein cholesterol (HDL-C) have been reported to be positively  
5  
6 correlated with the serum uric acid level, while the serum HDL-C level inversely<sup>13</sup>.  
7  
8  
9 Juraschek *et al.* found a 4-fold or higher prevalence of hyperuricemia in individuals  
10  
11 who had blood pressure uncontrolled and were exposed to other risk factors of  
12  
13 cardiovascular diseases <sup>14</sup>.  
14  
15

16  
17 It is generally believed that obesity is closely associated with metabolism-related  
18  
19 diseases, and it increases the risk of developing diabetes, NAFLD and hyperuricemia.  
20  
21 Recently, more and more studies have shifted their attention to metabolic disorders in  
22  
23 the non-obese population. Some studies showed that the non-obese population could  
24  
25 also present a high prevalence of NAFLD. For example, as we previously reported,  
26  
27 the prevalence of NAFLD in a non-obese Chinese population was 7.3%<sup>15</sup>. A study  
28  
29 from Japan warned that more than 60% of Japanese diabetic subjects are non-obese<sup>16</sup>.  
30  
31 The findings suggest that it be important to assess metabolic abnormalities in  
32  
33 non-obese individuals. So far, there has still been a paucity of studies on  
34  
35 hyperuricemia in the non-obese population.  
36  
37  
38  
39  
40  
41  
42

43 In this study, we conducted a retrospective cross-sectional analysis on a non-obese  
44  
45 Chinese population to evaluate the prevalence of hyperuricemia and determine its  
46  
47 associated factors.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods

### Study population

The study population of this cross-sectional study was adults who took their health checkups at the First Affiliated Hospital, Zhejiang University School of Medicine from January 1 to December 31, 2019. Following the hospital's standard health checkup protocol, all participants received medical history collection, anthropometric measurement, blood examination, and abdominal ultrasound examination. For research purpose, we collected these data from their checkup reports and excluded participants meeting the following criteria: (1) those with BMI  $\geq 24$  kg/m<sup>2</sup>; (2) those with incomplete anthropometric and biochemical data; (3) those with a history of malignancy; and (4) those under urate-lowering treatment. A total of 10908 participants were enrolled in this study, 4120 of whom had a BMI greater than 24 kg/m<sup>2</sup>, 684 had incomplete data, 114 had a history of malignancy, and 259 took urate-lowering drugs. Finally, this study qualified 5731 participants (including 2349 men and 3382 women)(Figure S1).

### Clinical evaluations

For all the participants undergoing the health checkup, anthropometric parameters including standing height, body weight, and waist circumference were measured. Blood pressure was gauged following a standard protocol. For height and weight, participants should be in light clothes with shoes taken off. BMI (kg/m<sup>2</sup>) was calculated as the body weight (kg) divided by the standing height (m) squared. Fasting



1  
2  
3  
4 serum samples were obtained for biochemical analysis with a Hitachi 7600 clinical  
5  
6 analyzer (Hitachi, Tokyo, Japan) in accordance with standard methods. Questions  
7  
8 about alcohol intake included frequency of alcohol consumption (per week) and usual  
9  
10 amount per day. Questions about smoking history included daily smoking count and  
11  
12 years of smoking.  
13  
14  
15

### 19 **Diagnostic criteria and definitions**

21  
22 BMI was adopted to define obesity. Non-obese was defined as BMI < 24 kg/m<sup>2</sup>,  
23  
24 and obesity is defined as BMI ≥24 kg/m<sup>2</sup>. Excessive drinking was defined as alcohol  
25  
26 consumption >210 g/week for men or >70 g/week for women. Hyperuricemia could  
27  
28 be diagnosed with the serum uric acid level >420 μmol/L for men or >360 μmol/L for  
29  
30 women<sup>8, 17, 18</sup>. The factor eGFR (estimated glomerular filtration rate) was calculated  
31  
32 using the modified MDRD formula<sup>19</sup>.  
33  
34  
35

37  
38 In the health checkup, all individuals underwent abdominal ultrasound  
39  
40 examination, which was performed by trained ultrasonographers with a Toshiba  
41  
42 Nemio 20 ultrasound system (Toshiba, Tokyo, Japan). The criteria for ultrasonic  
43  
44 diagnosis of fatty liver were based on those suggested by the Chinese Liver Disease  
45  
46 Association<sup>20</sup>.  
47  
48  
49

51  
52 Metabolic syndrome was defined according to the modified National Cholesterol  
53  
54 Education Program Adult Treatment Panel III report<sup>21</sup>. Participants diagnosed with  
55  
56 metabolic syndrome must have three or more of the following factors: (1) central  
57  
58 obesity, defined as waist circumference >102 cm for men or >88 cm for women; (2)  
59  
60

1  
2  
3  
4 raised serum triglyceride level, defined as triglyceride  $\geq 1.7$  mmol/L or specific  
5  
6 treatment for this lipid abnormality; (3) reduced HDL cholesterol, defined as HDL  
7  
8 cholesterol  $<1.03$  mmol/L for men or  $<1.29$  mmol/L for women; (4) elevated blood  
9  
10 pressure, defined as systolic blood pressure  $\geq 130$  mmHg or diastolic blood pressure  
11  
12  $\geq 85$  mmHg, or treatment of previously diagnosed hypertension; and (5) raised fasting  
13  
14 blood sugar, defined as fasting blood sugar  $\geq 6.1$  mmol/L, or previously diagnosed  
15  
16 type 2 diabetes. Metabolically unhealthy participants were defined as those who met  
17  
18 the criteria of metabolic syndrome.  
19  
20  
21  
22  
23  
24  
25  
26

### 27 **Statistical analyses**

28  
29  
30 The statistical analyses were performed using SPSS 18.0 (SPSS, Chicago, IL).  
31  
32 Continuous variables were presented as mean and 95% confidence interval (CI) and  
33  
34 compared by Student's *t* test or Mann-Whitney *U* test as appropriate. Categorical  
35  
36 variables were compared using the  $\chi^2$  test. A stepwise logistic regression approach  
37  
38 was introduced to explore the association of hyperuricemia with anthropometric or  
39  
40 biochemical parameters (probability to enter = 0.05 and probability to remove = 0.10).  
41  
42  
43 It was considered that  $P < 0.05$  (two-tailed test) was statistically significant.  
44  
45  
46  
47  
48  
49

### 50 **Ethics**

51  
52  
53 During the health checkup, all participants were informed of the potential use of their  
54  
55 checkup data for future research and that subject information would be anonymized at  
56  
57 collection prior to research analysis. All methods were performed in accordance with  
58  
59  
60

1  
2  
3  
4 the approved guidelines. The study was approved by the Clinical Research Ethics  
5  
6 Committee of the First Affiliated Hospital, Zhejiang University School of Medicine  
7  
8  
9 (No.2021015). Written consent was not required because of the retrospective  
10  
11 observational design of the study.  
12  
13  
14  
15  
16

### 17 **Patient and public involvement**

18  
19 Patients or the public were not involved in the design, conduct, report, or  
20  
21 dissemination of our research.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Results

### Prevalence of hyperuricemia in the non-obese population

A total of 5731 non-obese participants (2349 men and 3382 women) with a mean age of  $44.6 \pm 12.0$  years were included in this study. The overall prevalence of hyperuricemia was 9.4% (16.3% in males and 4.6% in females). In non-obese males, the prevalence of hyperuricemia was stable before the age of 50, and gradually decreased after 50. Conversely, in non-obese females, the prevalence of hyperuricemia decreased with age before the age of 50, and gradually increased after 50. An interesting finding was that the prevalence of hyperuricemia in females was even higher than that in males after the age of 65 (Figure 1).

We compared the clinical characteristics of participants with or without hyperuricemia in both genders (Table 1). We found that hyperuricemic participants showed greater BMI (22.33 (22.19–22.47) versus 21.87 (21.80–21.94)  $\text{kg}/\text{m}^2$ ,  $p < 0.001$  in males; 21.64 (21.36–21.92) versus 20.94 (20.88–21.00)  $\text{kg}/\text{m}^2$ ,  $p < 0.001$  in females) and waist circumference (83.1 (82.6–83.6) versus 81.3 (81.1–81.5) cm,  $p < 0.001$  in males; 76.6 (75.5–77.7) versus 74.0 (73.8–74.2) cm,  $p < 0.001$  in females), higher diastolic blood pressure (77.2 (76.1–78.3) versus 75.6 (75.1–76.1) mmHg,  $p = 0.006$  in males; 73.9 (72.1–75.7) versus 69.2 (68.8–69.6) mmHg,  $p < 0.001$  in females), and worse lipid profiles than those without hyperuricemia. Hyperuricemic participants also had higher serum levels of alanine aminotransferase (ALT) (26.5 (24.7–28.4) versus 21.4 (20.6–22.3) U/L,  $p < 0.001$  in males; 23.2 (18.4–28.0) versus 15.2 (14.9–15.6) U/L,  $p = 0.001$  in females), aspartate aminotransferase (AST)

1  
2  
3  
4 (22.5 (21.6 – 23.5) versus 20.6 (20.1 – 21.0) U/L,  $p=0.001$  in males; 23.1 (20.5 – 25.7)  
5  
6  
7 versus 18.4 (18.1 – 18.6) U/L,  $p=0.001$  in females), gamma–glutamyl transpeptidase  
8  
9 (GGT) (41.6 (37.7 – 45.6) versus 30.1 (29.1 – 32.9) U/L,  $p<0.001$  in males; 22.9  
10  
11 (19.5 – 26.3) versus 16.8 (16.2 – 17.5) U/L,  $p<0.001$  in females), blood urea nitrogen  
12  
13 (BUN) (5.37 (5.21 – 5.53) versus 5.12 (5.07 – 5.17) mmol/L,  $p=0.003$  in males; 5.07  
14  
15 (4.84 – 5.30) versus 4.55 (4.51 – 4.59) mmol/L,  $p<0.001$  in females), and creatinine  
16  
17 (86.5 (84.6 – 88.4) versus 81.2 (80.6 – 81.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in males; 63.8 (62.2 –  
18  
19 65.4) versus 59.5 (59.2 – 59.8)  $\mu\text{mol/L}$ ,  $p<0.001$  in females) than normouremic  
20  
21  
22  
23  
24  
25 participants.

### 26 27 28 29 30 **Association of hyperuricemia with metabolic disorders in the non-obese** 31 32 **population**

33  
34  
35 We classified all the non-obese participants into metabolically healthy normal  
36  
37 weight (MHNW) group and metabolically unhealthy normal weight (MUHNW)  
38  
39 group, according to their metabolic status. We found that MUHNW participants had a  
40  
41 significantly higher prevalence of hyperuricemia than MHNW participants. In detail,  
42  
43 the prevalence of hyperuricemia increased from 15.6% in MHNW participants to  
44  
45 26.7% in MUHNW participants in males ( $p<0.001$ ). Similarly, the prevalence of  
46  
47 hyperuricemia increased from 4.1% in MHNW participants to 16.3% in MUHNW  
48  
49  
50  
51 participants in females ( $p<0.001$ ) (Figure 2).  
52  
53  
54

55  
56 We also analyzed the prevalence of metabolic disorders in non-obese individuals  
57  
58 with or without hyperuricemia. We found that the prevalence of metabolic syndrome  
59  
60

1  
2  
3  
4 were significantly higher in hyperuricemic participants (male 10.2%, female 16%)  
5  
6 than in normoureemic participants (male 5.4%, female 4%;  $p < 0.001$  in both genders).  
7  
8

9 We also found that the prevalence of fatty liver disease were significantly higher in  
10  
11 hyperuricemic participants (male 30.4%, female 20.5%) than in normoureemic  
12  
13 participants (male 13.8%, female 6.4%;  $p < 0.001$  in both genders). Male  
14  
15 hyperuricemic participants had a higher prevalence of raised triglyceride level and  
16  
17 reduced HDL-C than normoureemic participants. Female hyperuricemic participants  
18  
19 had a higher prevalence of raised triglyceride level, reduced HDL-C, elevated blood  
20  
21 pressure, and raised fasting blood sugar than normoureemic participants (Table 2).  
22  
23  
24  
25  
26  
27 However, the prevalence of diabetes was not different between the two groups (Table  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Factors associated with hyperuricemia among the non-obese population**

We adopted a stepwise logistic regression approach to analyze the factors associated with hyperuricemia. The multivariable model showed that greater waist circumference values (1.057 (1.030–1.084) (the data was expressed as OR (95%CI) , the same below) in males and 1.038 (1.006–1.071) in females), elevated BUN levels (1.114 (1.014–1.223) in males and 1.308 (1.137–1.505) in females), excessive drinking (1.501 (1.097–2.055) in males and 3.562 (1.408–9.011) in females) and presence of fatty liver (1.959 (1.472–2.607) in males and 1.900 (1.164–3.102) in females) were associated with an increased prevalence of hyperuricemia in both genders. Greater age (0.961 (0.950–0.972) in males and 0.958 (0.939–0.977) in

1  
2  
3  
4 females) and elevated eGFR levels (0.973 (0.965–0.980) in males and 0.976 (0.966–  
5  
6 0.985) in females) were associated with a decreased prevalence of hyperuricemia in  
7  
8 both genders. Elevated serum levels of AST (1.014 (1.004–1.024)) and total  
9  
10 cholesterol (2.717 (1.921–3.843)) were associated with an increased prevalence of  
11  
12 hyperuricemia in males. Elevated serum levels of HDL-C (0.378 (0.240–0.594)) and  
13  
14 LDL-C (0.386 (0.256–0.583)) were associated with a decreased prevalence of  
15  
16 hyperuricemia in males. Elevated diastolic blood pressure (1.033 (1.016–1.050)),  
17  
18 higher ALT (1.023 (1.013–1.033)) and triglyceride (1.423 (1.199–1.690)) levels were  
19  
20 associated with an increased prevalence of hyperuricemia in females (Table 3).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Discussion

This study investigated the prevalence and factors associated with hyperuricemia in a non-obese Chinese population. We found that the prevalence of hyperuricemia was 9.4% in the non-obese adults, with 16.3% in men and 4.6% in women. Age, waist circumference, eGFR, BUN, excessive drinking and presence of fatty liver were associated with hyperuricemia in both genders.

The prevalence of hyperuricemia in non-obese individuals was 9.4%, lower than that previously reported in the general population in East Asia<sup>10,22</sup>, which included both non-obese and obese individuals as a whole, rather than separately. We found that in the non-obese individuals, the overall prevalence of hyperuricemia was higher in men than in women. However, the prevalence of hyperuricemia increased greatly in women older than 50, which could be corroborated by other studies<sup>23,24</sup>. A possible explanation could be the effects of sex hormones on renal urate transport. Estrogen affects serum uric acid level through renal clearance, secretion and reabsorption. Serum urate level is generally lower in young adult women than in their male counterparts, while the onset of menopause has been reported to correlate with an increased serum urate level<sup>25</sup>.

At the same time, we found that the prevalence of hyperuricemia gradually decreased with age in male non-obese patients, which was inconsistent with previous studies<sup>26,27</sup>. One possible reason was that we have excluded patients undergoing urate-lowering treatment in our study. Nowadays, as the prevalence of gout increases



1  
2  
3  
4 significantly with age, the number of patients taking urate-lowering treatment is also  
5  
6 on the rise as age grows, which may lead to a selection bias in our research<sup>28, 29</sup>.  
7  
8

9 Some studies have reported the interaction between hyperuricemia and NAFLD.  
10  
11 We previously reported that hyperuricemia is independently associated with the risk  
12  
13 of NAFLD<sup>6</sup>. Our previous prospective study also found that NAFLD was strongly  
14  
15 associated with an increased risk of incident hyperuricemia<sup>8</sup>. In this study, we  
16  
17 identified fatty liver as a factor associated with hyperuricemia in the non-obese  
18  
19 population. Our results suggested that the interaction between hyperuricemia and  
20  
21 metabolic disorders should also be paid attention to in the non-obese population, to  
22  
23 prevent further progression to deteriorated metabolic status.  
24  
25  
26  
27  
28  
29

30 MUHNW, generally defined as normal weight with metabolic syndrome, has  
31  
32 raised considerable scientific interest<sup>30</sup>. Individuals with a metabolically unhealthy  
33  
34 profile were associated with several health issues and higher healthcare and  
35  
36 loss-of-productivity costs<sup>31</sup>. The risk of CVD in MUHNW individuals was 1.5–3-fold  
37  
38 higher than that in MHNW individuals, and higher than the relative risk in those with  
39  
40 metabolically healthy obesity (MHO)<sup>32</sup>. It is not rare to find that MUHNW  
41  
42 individuals have a worse prognosis of diabetes than MHO individuals<sup>33</sup>. In this study,  
43  
44 we found that the prevalence of hyperuricemia increased significantly in MUHNW  
45  
46 participants compared with that in MHNW participants. This phenomenon was more  
47  
48 obvious in women, which implied that we could pay more attention to serum uric acid  
49  
50 level in MUHNW individuals. As they are more likely to suffer from hyperuricemia,  
51  
52 early intervention in uric acid level may benefit these patients by protecting them  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 from developing further metabolic disorders<sup>34</sup>.  
5

6 We next assessed the comorbidity of other metabolic disorders in non-obese  
7  
8 hyperuricemic patients. We found that the prevalence of metabolic syndrome and of  
9  
10 fatty liver disease in non-obese hyperuricemic participants were higher than those in  
11  
12 normouricemic controls. This indicated that hyperuricemia in the non-obese population  
13  
14 could also be accompanied by multiple metabolic disorders. Studies have reported  
15  
16 hyperuricemia as a cause of metabolic syndrome<sup>7</sup>. Our previous studies also found  
17  
18 that hyperuricemia could promote the occurrence and development of NAFLD, and  
19  
20 urate-lowering treatment could alleviate NAFLD<sup>8</sup>. Therefore, non-obese  
21  
22 hyperuricemic individuals may also need active intervention in uric acid level to  
23  
24 reduce the risk of comorbid metabolic disorders<sup>35</sup>.  
25  
26  
27  
28  
29  
30  
31

32 Several limitations are acknowledged for this study. First, due to the single-center  
33  
34 design and the limited sample size, the results of this study may not apply to the entire  
35  
36 Chinese adult population. Further multi-center cohort studies are needed. Second, in  
37  
38 our study, patients currently undergoing urate-lowering treatment were excluded,  
39  
40 which might cause a selection bias in the prevalence of hyperuricemia. In our  
41  
42 research, some factors related to uric acid were not included, such as gout, renal  
43  
44 disease, and treatment with diuretics, etc. Third, several studies have demonstrated  
45  
46 that fructose-enriched foods and drinks lead to increased serum UA levels<sup>36</sup>,  
47  
48 indicating the role of dietary intake in the development of hyperuricemia. Dietary  
49  
50 information, however, was not unavailable in the checkup reports and thus was not  
51  
52 discussed in this study. Meanwhile, this study defined the non-obese participants by  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 BMI without including waist circumference or waist-to-hip ratio. Some central obese  
5  
6 patients could be mixed in the non-obese participants.  
7  
8

9 In conclusion, our retrospective cross-sectional study showed that the prevalence  
10  
11 of hyperuricemia was 9.4% in the non-obese Chinese population. The prevalence of  
12  
13 hyperuricemia increased significantly in MUHNW participants compared with  
14  
15 MHNW participants. Hyperuricemia in non-obese people could also be accompanied  
16  
17 by multiple metabolic disorders. Therefore, we suggest that clinicians pay attention to  
18  
19 serum uric acid level in non-obese patients.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **Fundings**

This work was supported by Health Science and Technology Plan Project of Zhejiang Province (No. 2021KY147, and 2021KY1129), Key Research and Development Program of Zhejiang Province (No. 2020C03033), and National Natural Science Foundation of China (Nos. 82070585, and 81770573).

## **Conflicts of interest**

The authors declare no conflicts of interest.

## **Author Contributions:**

Conceived and designed the experiment: X.C.F. and Z.H.L. Collected the clinical information: W.J.H, C.Y.S. and C.S.H. Analyzed the data: W.J.H, W.X.Y. and Z.H.L. Wrote the paper: W.J.H. and C.Y.S. All authors reviewed the manuscript.

## **Data Availability Statement**

Data are available upon reasonable request.

## References

1. Singh G, Lingala B, Mithal A. Gout and hyperuricaemia in the USA: prevalence and trends. *Rheumatology (Oxford)* 2019; 58(12): 2177-80.
2. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of Obesity: a Longitudinal Population-Based Epidemiological Study. *Clin Lab* 2017; 63(10): 1581-87.
3. Son M, Seo J, Yang S. Association between dyslipidemia and serum uric acid levels in Korean adults: Korea National Health and Nutrition Examination Survey 2016-2017. *PLoS One* 2020; 15(2): e0228684.
4. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. *Curr Opin Rheumatol* 2013; 25(2): 210-6.
5. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. *Curr Hypertens Rep* 2016; 18(10): 74.
6. Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. *J Hepatol* 2009; 50(5): 1029-34.
7. King C, Lanaspa MA, Jensen T, Tolan DR, Sanchez-Lozada LG, Johnson RJ. Uric Acid as a Cause of the Metabolic Syndrome. *Contrib Nephrol* 2018; 192: 88-102.
8. Xu C, Wan X, Xu L, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. *J Hepatol* 2015; 62(6): 1412-9.
9. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 2011; 63(10): 3136-41.
10. Liu R, Han C, Wu D, et al. Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis. *Biomed Res Int* 2015; 2015: 762820.
11. Wan Z, Song L, Hu L, Lei X, Huang Y, Lv Y. Temporal trends in hyperuricaemia among adults in Wuhan city, China, from 2010 to 2019: a cross-sectional study. *BMJ Open* 2021; 11(3): e043917.
12. Ni Q, Lu X, Chen C, Du H, Zhang R. Risk factors for the development of hyperuricemia A STROBE-compliant cross-sectional and longitudinal study. *Medicine* 2019; 98: 42.
13. Peng TC, Wang CC, Kao TW, et al. Relationship between hyperuricemia and lipid profiles in US adults. *Biomed Res Int* 2015; 2015: 127596.
14. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout. *PLoS One* 2013; 8(2): e56546.
15. Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. *Am J Gastroenterol* 2013; 108(8): 1299-304.
16. Kashima S, Inoue K, Matsumoto M, Akimoto K. Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study. *J Diabetes* 2015; 7(4): 523-30.
17. Huang YF, Yang KH, Chen SH, et al. [Practice guideline for patients with hyperuricemia/gout]. *Zhonghua Nei Ke Za Zhi* 2020; 59(7): 519-27.
18. Zhang Y, Nie FQ, Huang XB, et al. High prevalence and low awareness of hyperuricemia in hypertensive patients among adults aged 50-79 years in Southwest China. *BMC Cardiovasc Disord* 2022; 22(1): 2.

19. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol* 2006; 17(10): 2937-44.
20. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver Disease CSOHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). *J Dig Dis* 2019; 20(4): 163-73.
21. Expert Panel on Detection E, Treatment of High Blood Cholesterol In A. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 2001; 285(19): 2486-97.
22. Kim Y, Kang J, Kim GT. Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample. *Clin Rheumatol* 2018; 37(9): 2529-38.
23. Gaffo AL, Jacobs DR, Jr., Lewis CE, Mikuls TR, Saag KG. Association between being African-American, serum urate levels and the risk of developing hyperuricemia: findings from the Coronary Artery Risk Development in Young Adults cohort. *Arthritis Res Ther* 2012; 14(1): R4.
24. Mcadams-Demarco MA, Law A, Maynard JW, Coresh J, Baer AN. Risk factors for incident hyperuricemia during mid-adulthood in African American and white men and women enrolled in the ARIC cohort study. *BMC Musculoskelet Disord* 2013; 14: 347.
25. Koga M, Saito H, Mukai M, Kasayama S, Yamamoto T. Factors contributing to increased serum urate in postmenopausal Japanese females. *Climacteric* 2009; 12(2): 146-52.
26. Song P, Wang H, Xia W, Chang X, Wang M, An L. Prevalence and correlates of hyperuricemia in the middle-aged and older adults in China. *Sci Rep* 2018; 8(1): 4314.
27. Cui L, Meng L, Wang G, et al. Prevalence and risk factors of hyperuricemia: results of the Kailuan cohort study. *Mod Rheumatol* 2017; 27(6): 1066-71.
28. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. *Nat Rev Rheumatol* 2020; 16(7): 380-90.
29. Robinson PC, Taylor WJ, Dalbeth N. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. *J Rheumatol* 2015; 42(9): 1702-7.
30. Lonardo A, Mantovani A, Lugari S, Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Ann Hepatol* 2020; 19(4): 359-66.
31. Samouda H, Ruiz-Castell M, Karimi M, et al. Metabolically healthy and unhealthy weight statuses, health issues and related costs: Findings from the 2013-2015 European Health Examination Survey in Luxembourg. *Diabetes Metab* 2019; 45(2): 140-51.
32. Schulze MB. Metabolic health in normal-weight and obese individuals. *Diabetologia* 2019; 62(4): 558-66.
33. Buscemi S, Chiarello P, Buscemi C, et al. Characterization of Metabolically Healthy Obese People and Metabolically Unhealthy Normal-Weight People in a General Population Cohort of the ABCD Study. *J Diabetes Res* 2017; 2017: 9294038.
34. Borghi C, Agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. *Eur J Intern Med* 2020; 80: 1-11.
35. Bove M, Cicero AF, Veronesi M, Borghi C. An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. *Vasc Health Risk Manag* 2017; 13: 23-28.

1  
2  
3 36. Caliceti C, Calabria D, Roda A, Cicero AFG. Fructose Intake, Serum Uric Acid, and  
4 Cardiometabolic Disorders: A Critical Review. *Nutrients* 2017; 9(4).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Table 1. Clinical characteristics of the study population

Variables	Male		P value	Female		P value
	Without hyperuricemia (n=1967)	With hyperuricemia (n=382)		Without hyperuricemia (n=3226)	With hyperuricemia (n=156)	
Age (year)	46.5(46.0-47.1)	44.5(43.3-45.7)	0.004	43.4(43.0-43.8)	46.6(44.3-49.0)	0.009
WC (cm)	81.3(81.1-81.5)	83.1(82.6-83.6)	<0.001	74.0(73.8-74.2)	76.6(75.5-77.7)	<0.001
BMI (kg/m <sup>2</sup> )	21.87(21.80-21.94)	22.33(22.19-22.47)	<0.001	20.94(20.88-21.00)	21.64(21.36-21.92)	<0.001
SBP (mmHg)	122.8(122.1-123.5)	124.1(122.4-125.8)	0.159	115.0(114.4-115.6)	122.2(119.0-125.4)	<0.001
DBP (mmHg)	75.6(75.1-76.1)	77.2(76.1-78.3)	0.009	69.2(68.8-69.6)	73.9(72.1-75.7)	<0.001
ALT (U/L)	21.4(20.6-22.3)	26.5(24.7-28.4)	<0.001	15.2(14.9-15.6)	23.2(18.4-28.0)	0.001
AST (U/L)	20.6(20.1-21.0)	22.5(21.6-23.5)	0.001	18.4(18.1-18.6)	23.1(20.5-25.7)	0.001
GGT (U/L)	30.1(29.1-32.9)	41.6(37.7-45.6)	<0.001	16.8(16.2-17.5)	22.9(19.5-26.3)	<0.001
Creatinine (μmol/L)	81.2(80.6-81.8)	86.5(84.6-88.4)	<0.001	59.5(59.2-59.8)	63.8(62.2-65.4)	<0.001
BUN (mmol/L)	5.12(5.07-5.17)	5.37(5.21-5.53)	0.003	4.55(4.51-4.59)	5.07(4.84-5.30)	<0.001
eGFR	101.1(100.4-101.8)	95.3(93.5-97.1)	<0.001	188.7(188.0-189.4)	109(105.4-112.6)	<0.001
TG (mmol/L)	1.38(1.34-1.42)	1.88(1.76-2.00)	<0.001	1.05(1.03-1.07)	1.60(1.28-1.92)	0.001
TC (mmol/L)	4.49(4.45-4.53)	4.71(4.62-4.80)	<0.001	4.52(4.49-4.55)	4.76(4.62-4.90)	0.001
HDL-C (mmol/L)	1.21(1.20-1.22)	1.14(1.11-1.17)	<0.001	1.44(1.43-1.45)	1.36(1.30-1.42)	0.003
LDL-C (mmol/L)	2.62(2.59-2.65)	2.72(2.65-2.79)	0.012	2.53(2.51-2.55)	2.65(2.53-2.77)	0.026
VLDL-C (mmol/L)	0.65(0.64-0.66)	0.84(0.80-0.88)	<0.001	0.55(0.54-0.56)	0.73(0.65-0.81)	<0.001
FBS (mmol/L)	5.02(4.97-5.07)	5.01(4.93-5.09)	0.815	4.81(4.79-4.83)	5.07(4.93-5.21)	<0.001
Excessive drinking (%)	14.0%(12.5%-15.5%)	19.4%(15.4%-23.4%)	0.007	1.4%(1.0%-1.8%)	3.8%(0.8%-6.8%)	0.016
Smoking history (%)	39.0%(36.8%-41.2%)	42.9%(37.9%-47.9%)	0.15	1.4%(1.0%-1.8%)	1.3%(0%-3.1%)	0.906
SUA (μmol/L)	333.8(331.6-336.0)	467.9(463.2-472.6)	<0.001	260.0(258.5-261.5)	397.1(390.8-403.4)	<0.001

Data are expressed as the mean (95% CI)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SBP: systolic blood pressure; SUA: serum uric acid; TG: triglyceride; TC: total cholesterol; VLDL-C: very low-density lipoprotein cholesterol; WC: waist circumference.



Table 2. Prevalence of metabolic disease according to hyperuricemia

	Male		<i>P</i> -value	Female		<i>P</i> -value
	Without hyperuricemia	With hyperuricemia		Without hyperuricemia	With hyperuricemia	
Metabolic syndrome	5.4%	10.2%	<0.001	4%	16%	<0.001
Metabolic syndrome components						
Waist circumference (> 102 cm in men, >88 cm in women)	0%	0%	/	1.4%	3.2%	0.06
Fasting blood glucose ( $\geq 6.1$ mmol/L)	6.4%	6.5%	0.890	2%	10.9%	<0.001
Triglyceride ( $\geq 1.7$ mmol/L)	21.9%	45%	<0.001	10.8%	26.3%	<0.001
HDL-C (<1.04 mmol/L in men, <1.30 mmol/L in women)	28.9%	37.7%	0.001	35.2%	48.1%	0.001
Blood pressure ( $\geq 130/85$ mmHg)	33.7%	38%	0.105	19.3%	35.9%	<0.001
Diabetes mellitus	3.4%	2.9%	0.599	1%	2.6%	0.062
NAFLD	13.8%	30.4%	<0.001	6.4%	20.5%	<0.001

HDL-C: high-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease;

Table 3. Multivariable analysis for factors associated with hyperuricemia

Variables	Male		Female	
	OR (95% CI)	P-value	OR (95% CI)	P-value
Age (year)	0.961(0.950-0.972)	<0.001	0.958 (0.939-0.977)	<0.001
WC (cm)	1.057 (1.030-1.084)	<0.001	1.038 (1.006-1.071)	0.020
DBP (mmHg)	/		1.033(1.016-1.050)	<0.001
ALT (U/L)	/		1.023 (1.013-1.033)	<0.001
AST (U/L)	1.014 (1.004-1.024)	0.005	/	
eGFR ( $\mu$ mol/L)	0.973 (0.965-0.980)	<0.001	0.976 (0.966-0.985)	<0.001
BUN (mmol/L)	1.114 (1.014-1.223)	0.025	1.308 (1.137-1.505)	<0.001
TG (mmol/L)	/		1.423 (1.199-1.690)	<0.001
TC (mmol/L)	2.717 (1.921-3.843)	<0.001	/	
HDL-C (mmol/L)	0.378 (0.240-0.594)	<0.001	/	
LDL-C (mmol/L)	0.386 (0.256-0.583)	<0.001	/	
Excessive drinking	1.501 (1.097-2.055)	0.011	3.562 (1.408-9.011)	0.007
NAFLD	1.959 (1.472-2.607)	<0.001	1.900 (1.164-3.102)	0.010

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FBS: fasting blood sugar; GGT: gamma-glutamyl transpeptidase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; NAFLD: nonalcoholic fatty liver disease; TG: triglyceride; TC: total cholesterol; WC: waist circumference

**Figure Legend**

Figure 1. Prevalence of hyperuricemia(A) and Serum uric acid(B) in participants

Data was expressed as mean with 95% confidence interval (error bars)

Figure 2. Prevalence of hyperuricemia (A) and Serum uric acid (B) in metabolically healthy or

metabolically unhealthy participants. Data was expressed as mean  $\pm$  SD. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .

For peer review only




Figure 1

121x114mm (300 x 300 DPI)




Figure 2

83x104mm (300 x 300 DPI)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure S1. Inclusion and exclusion flow chart of this study

**STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies***

Section/Topic	Item #	Recommendation	Reported on page #
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6-7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-7
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6-7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	8
<b>Results</b>			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	9
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	9-10
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	9-10
		(b) Report category boundaries when continuous variables were categorized	9-10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	9-10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	11
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	11-12
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	11-12
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-13
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).